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Abstract
Donation after cardiac death (DCD) grafts experience prolonged ischemia reperfusion injury
(IRI) leading to higher rates of delayed graft function and failure. Recent studies have
reported protective effects of hydrogen sulfide (H2S) against IRI. Our study aims at
improving DCD renal graft outcomes by H2S supplementation in an in-vivo murine model of
renal transplantation (RTx) and study the underlying mechanism in an in-vitro model using
porcine kidney proximal-tubular-epithelial cells (LLC-PK1). H2S provided survival benefit,
improved renal graft function and decreased renal injury in recipient rats. In our in-vitro
model of LLC-PK1 cells, H2S demonstrated an important role mediated by mitochondria in
the pathophysiological effects of IRI by reducing depolarization of the mitochondrial
membrane and the amount of reactive oxygen species. In the long run, these findings would
help bridge the gap between organ demand and supply by reducing the extent of renal IRI
and delayed graft function in DCD donors.

Keywords
Ischemia reperfusion injury, donation after cardiac death, kidney transplantation, rats,
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mitochondria, apoptosis, necrosis.
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Chapter 1

1

Introduction

1.1 Kidney Disease
Kidneys are one of the vital organs in our body responsible for maintaining the normal
physiological conditions. On average, a person’s kidneys weigh around 115grams and are
responsible for processing about 180 liters of blood to remove waste and toxic products
such as urea and ammonium along with excess water.1 Being the major excretory organs
besides the gastrointestinal tract, they also play a role in metabolic and biosynthetic
functions such as the regulation of renin that regulates blood volume and pressure1, and
red blood cell formation via erythropoietin synthesis.1,2
In some individuals, the kidneys stop working optimally and this leads to chronic kidney
disease (CKD). CKD, as defined by the National Kidney Foundation (NKF), is either
kidney damage or decreased kidney function [as measured by decreased Glomerular
Filtration Rate (GFR) of less than 60mL/min/1.73m2] for three or more months.3 The loss
of kidney function is gradual and can remain undetected for a long time. Currently, there
are 26 million American adults that have CKD and several others are at an increased
risk.2 Some factors that are known to increase a person’s vulnerability to the development
of CKD are high blood pressure/chronic hypertension, diabetes and old age.2,3 About 50%
of kidney failure cases are linked to diabetes while 30% are associated with
hypertension.4 Other conditions such as polycystic kidney disease, lupus,
glomerulonephritis and malformations during embryonic development may also affect the
kidneys leading to a greater risk of CKD.3
NKF has identified and classified CKD into five different stages based on the severity of
kidney function loss measured by decreased GFR. Progression of CKD from its mildasymptomatic stages to the late stages happens gradually. The final stage of CKD is
called the End Stage Renal Disease (ESRD) and is often described as the kidney failure
with the GFR being less than 15mL per minute per 1.73m2.1 Upon progression into this

2

stage, the patient either needs to receive regular dialysis treatments or undergo renal
transplantation.

1.2 Treatment Options for ESRD
The prevalence rate for ESRD in 2012 was reported to be 1182 per million in Canada and
has been increasing for the past few years.5 The ESRD patients experience a lot of
physical conditions including but not limited to fatigue, anorexia, pain, sleep problems,
anxiety and depression.6 In addition, the risk of developing cardiovascular diseases in
patients suffering from ESRD is almost 100 times of what is expected in the average
population.7 The treatment options available to the ESRD patients are summed under the
term renal replacement therapy (RRT) and include dialysis and renal transplant.8 In 2012,
about 58% of the ESRD patients were being treated with dialysis while 42% were living
with a functional kidney transplant in Canada.5

1.2.1 Dialysis: definition and types
Dialysis, at a biochemical level, is defined as the separation of substances in solution by
means of their unequal diffusion across a semipermeable membrane.9 In medical terms, it
generally refers to the removal of wastes or toxins from the blood and restoring the
electrolyte and fluid balance by the use of differential diffusion rates of different
substances through a semipermeable membrane.10
There are two types of dialysis – hemodialysis and peritoneal dialysis.11 Hemodialysis
came into practice in 1960’s10 and is the most commonly used method of dialysis. It
requires access to the patient’s circulatory system. 9,10 The blood is pumped into the
dialyzer for filtration from the artery. Following the removal of excess fluids and waste
products, it is pumped back into the vein. The semi-permeable membranes installed in the
dialyzer help carry out the process of diffusion. On the other hand, peritoneal dialysis
involves the use of peritoneum as the semi-conservative membrane that enables the
exchange of electrolytes, fluids and waste products.12 The major difference between these
two types of dialysis is that hemodialysis needs assistance of medical personnel and is
generally carried out in designated sections of hospitals while the peritoneal dialysis can
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be carried out at home without visiting any medical facility.10,13 However, both types of
dialysis are life saving and help in improving a patient’s quality of life.14,15

1.2.2 Advantages and disadvantages associated with dialysis
The major advantage for dialysis treatments is zero wait times associated with the
initiation of the procedure. When an individual is diagnosed with CKD and needs external
assistance in the filtration of blood, immediate help is available at medical facilities upon
physician’s recommendation. However, some disadvantages include experiencing a
feeling of being sick following the dialysis treatment due to the drainage of energy,
incidents of hypo/hyper-tension, muscle cramping, restless leg syndrome, anemia and
nausea / vomiting.16,17 In addition, the hemodialysis treatment involves spending several
hours three times a week at the hospital, thereby compromising the quality of life of these
patients.12,14 The frequency and time of the treatments impose a lot of limitations on a
patient’s life such as travel, ability to work and time commitment.

1.2.3 Renal transplant
Renal transplant is defined as the medical procedure involving the placement of the donor
kidney into the patient suffering from ESRD.18 It is the treatment of choice for most
ESRD patients and generally happens after a prolonged time of dialysis treatments due to
the nature of the timeline involved in receiving a transplant. The process begins when the
physician prognosis ESRD in the patient and continues until a suitable donor kidney is
available. However, the whole process of finding a donor kidney is time consuming and
can take up to 3-7 years from the time of placement on the waitlist to receiving a kidney
transplant.19,20
As a result of the long wait times, many ESRD patients who do not have a living donor
available, die waiting for a donor organ. According to the United States Renal Data
System, 4270 patients died in the year 2014 while waiting for a renal transplant and
another 3617 patients became too sick to receive the transplant.18,21 Yet, the wait list
continues to grow with each passing year.21
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1.2.4 Types of organ donors
There are two categories of organ donors that are used for renal transplantation – living
donors and deceased/cadaveric donors.8 The ideal group for organ donation is the living
donors. A living donor (for renal transplantation) is an individual who donates one kidney
to someone in need of a transplant (ESRD patient) as the donor can survive on a single
healthy kidney. In most cases, the living donor is somehow related to the recipient and
this helps to reduce the wait time for finding a biologically compatible donor kidney
[based on blood group (ABO) and human leukocyte antigen (HLA) compatibility]. On the
other hand, the organs from the deceased donors are procured after declaration of brain or
cardiac death. Generally speaking, the growing wait times for receiving a deceased
donor’s kidney are due to the limited number of organ donors and increased number of
patients along with the significant number of kidneys that are deemed unsuitable for
transplantion (discarded organs).8
In 2012, a total of 17,305 kidney transplants were performed in United States which
included 5617 kidneys from living donors and 11,535 kidneys from the deceased donor
pool.21 This shows that the deceased donors contribute a larger proportion of the total
kidney transplants performed than do the living donors. Unfortunately, kidneys donated
by the deceased donors have a four percent higher chances of graft failure (measured by
factors like the patient’s return to dialysis, repeat transplantation or death) in comparison
to that from living donors.21
Further, in order to meet the organ shortage, the regulations for selecting deceased donor
kidneys for transplantation have become less stringent. Until the year 2005, the only
acceptable deceased organ donors for renal transplantation were the ones that belonged to
a younger age group (19 - 44 years old) who had died from brain injuries, often referred
to as the brain dead donors or donation after brain death (DBD).22,23 In these cases,
minimal injury was experienced by the donated kidneys because the blood supply to the
kidney was intact. However, the number of organs from the brain dead donors and living
donors were not enough to meet the organ demand in USA.
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The other potential opportunity to meet the organ shortage was the use of donation after
cardiac death (DCD) organs. DCD is widely accepted as an important source of organ
procurement in other developed countries like United Kingdom and Australia.22 However,
the use of DCD organs was limited in Canada until the year 2005. The new ethical
guidelines and policies that came into effect the same year permitted the use of DCD
donors in Canada.24,25 The rate of DCD transplants has increased eight fold over the last
two decades.26 The DCD donors are of two types – controlled and uncontrolled. The
uncontrolled DCD donors are found to be dead upon arrival and have either not been
resuscitated or resuscitated unsuccessfully.26 The controlled DCD organ donors are
typically the patients in intensive care units receiving life-sustaining treatments that have
suffered a non-recoverable brain injury. However, they fail to fulfill the criteria for the
donation after brain death. In these cases, permission is requested from the patient’s
family prior to the planned withdrawl of life support leading to a controlled DCD.27
After the withdrawl of life-support, a period of time passes until death can be pronounced
by cardiac arrest. This time period is highly variable during which time the organs are
vulnerable to ischemic. Following cardiac arrest, death cannot be pronounced until five
minutes after. Thereafter, the donor is taken to the operation room for organ procurement.
Upon procurement, the organs are perfused with the cold storage solution until the time of
transplantation in the recipient.28
In the controlled DCD, the procured organs experience longer periods of warm ischemic
stress during the period of time between discontinuation of life support and pronunciation
of death. This is further exacerbated by the long periods of cold storage (cold ischemia)
time leading to complications in the graft functioning upon transplantation.24,28,29 As a
result, the risk of delayed graft function and primary non function rate are significantly
increased in DCD renal transplants (compared to DBD organs) thereby necessitating the
need for dialysis during the first week following transplantation.27,30,31

1.2.5 Pros and cons of renal transplant
The major determinant of patient outcomes after transplantation is the long wait time
experienced by the patients on the waitlist before receiving the transplant. On average, a
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person encounters 3.6 years of wait time before receiving a transplant.21 Due to the long
wait times, the patients spend more years on dialysis which increases the risks of
cardiovascular disease associated mortality in these patients.32 In addition, patients
experience increased risk of infection and cancer associated with the immunosuppressive
drugs taken for the rest of their lives in order to prevent graft rejection.32-34

1.2.6 Effectiveness of renal transplant over dialysis
Renal transplantation offers ESRD patients an improved quality of life (QOL), increased
life expectancy or survival advantage, decreasing the insults to cardiovascular system
thereby lowering risk of cardiovascular diseases (CVD), decreased mortality and lower
economic burden/costs.35–38
Many studies have reported a higher quality of life in patients that undergo renal
transplantation to their counterparts that remained on the wait list with regular dialysis
treatments.32,35,36 The major factors that contribute to the improved quality of life in renal
transplant recipients include physical function/ability, greater independence, engagement
in social and recreational activities, and increased ability to work.25 In addition to
improved QOL, a 41% - 68% decrease in mortality has been reported in renal transplant
recipients in comparison to those that tend to remain on the wait list. 39,40
Over years, maintenance dialysis increases the risk of CVD associated mortality while the
patients that are able to maintain the graft function following renal transplantation show
continuous low CVD associated death rates, implying a long term reduction in the disease
progression.41 In addition to the various medical benefits, there is a 3.5 fold more
expensive to remain on dialysis versus a renal transplant. Surprisingly, renal
transplantation and maintenance cost much less (~$250,000 less over a period of 5 years)
than dialysis in the long term.37,42
All the above-mentioned factors make renal transplantation a better option for patients
affected with ESRD.
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1.3 Ischemia/Reperfusion Injury
Ischemia/reperfusion injury (IRI) is a pathological condition. As the name suggests, IRI is
made up of two parts – ischemia and reperfusion. Ischemic injury happens when the
blood supply to the organ is cut off leading to limited delivery of nutrients and oxygen.43
Reperfusion follows ischemia with the subsequent restoration of the blood supply to the
specific organ. Paradoxically, the restoration of blood supply to the organ enhances the
cellular inflammatory responses that lead to IRI.44 It is known to be inevitable in the
donated organs thereby impacting the functionality of the grafts after transplantation.

1.3.1 IRI effects at cellular level
There are multiple ways in which IRI can cause damage to a cell and these damages
ultimately result in cell death through apoptosis, necrosis or autophagy.43 Apoptosis is
caused by the action of intracellular signaling pathways that involve cellular caspases
(caspase 3 and caspase 9). These caspases cleave the cytoskeletal proteins leading to the
breakdown of the subcellular components.45,46 The main characteristics observed during
apoptosis are the shrinkage of the nucleus and cell, chromatin condensation and nuclear
fragmentation.47 Necrosis, on the other hand, is the cell death caused by swelling and
eventual bursting. It happens due to the loss in integrity of cell membrane causing influx
of the extracellular ions and fluid.47 Autophagy is different from apoptosis and necrosis. It
occurs on a daily basis and is defined as a pre-programmed cell death by means of which
the cells are able to recycle the unnecessary or damaged organelles and macromolecular
components.48,49 However, under conditions of hypoxic stress and nutrient deprivation,
our body uses this mechanism to provide the required substrates to the cells for
metabolism.47
During IRI, the hypoxic conditions limit the availability of oxygen molecules. The cells
need oxygen as the final acceptor of electrons in the electron transport chain in
mitochondria. Due to the lack of oxygen, the powerhouses of the cell (mitochondria)
produce reduced amount of energy in the form of adenosine triphosphate (ATP)
molecules and fulfill the needs of the cell.50,51 As a result, a number of ATP dependent
ion channels in the cell membrane fail to function properly and it gradually leads to the
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imbalance of cytoplasmic ions such as calcium (Ca+2), sodium (Na+) and hydrogen (H+).50
This can lead to calcium overload that activates calcium dependent enzymes resulting in
cell death or apoptosis. The hypoxic conditions also trigger the production of reactive
oxygen species (ROS) in the mitochondria. These are free radicals and reactive molecules
generated by molecular oxygen in the mitochondrial electron transport chain and include
superoxides, hydroxyl anions and hydrogen peroxides. In addition, the hypoxic stress can
cause the depolarization of mitochondrial membrane leading to a transition in the
mitochondrial membrane permeability (MMPT).50,52 Due to the decreased membrane
potential, high molecular weight molecules are now able to freely pass through the
mitochondrial membrane into the cytoplasm through the special channels and cause
cellular damage.53
There are a number of proteins induced by I/R that play a major role in apoptosis and act
in the mitochondria. The most well studied among these is the B-cell lymphoma (Bcl)
protein family, which contains both pro-apoptotic (Bax, Bid) and anti-apoptotic members
(Bcl-2, Mcl-1). It has been shown that the apoptotic process is initiated by caspase-8 that
truncates the cytosolic protein Bid into tBid (Figure 1). The truncated tBid binds to the
external mitochondrial membrane leading to the activation of Bax and Bak.54 Upon
activation, these proteins tend to oligomerize in the mitochondrial outer membrane
triggering the channels in the mitochondrial membrane that cause leakage of cytochrome
c into the cytoplasm.55 When cytochrome c reaches the cytoplasm, it mediates formation
of the apoptosome auto activating caspase 9. Active caspase 9 feeds the conversion of
pro-caspase 3 into active caspase 3 which triggers eventual apoptosis.56,57
Endogenously produced gaseous messenger molecules (gasotransmitters – discussed in
the upcoming section) have been shown to be helpful in mitigating some effects of IRI
however, their mechanism of action has not been elicited yet and is of great interest to the
scientists.
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Figure 1: Mitochondria associated apoptotic pathway.
Representative image showing the role played by pro-apoptotic and anti-apoptotic
molecules in apoptosis. The process can be initiated in the cells by hypoxia-induced stress
that initiates the signaling pathway resulting in the activation of pro-caspase-3. The
activated caspase-3 finally triggers apoptosis. (ROS – reactive oxygen species). 54-57
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1.4 Gasotransmitter family
Living beings contain a wide variety of signaling molecules ranging in size and chemical
properties. They can be proteins, lipids, amines, or even gases. A gasotransmitter is
defined as a gaseous messenger molecule that can activate a signaling process at the
cellular level. For classification purposes, it must meet the conditions listed in Table 1 to
qualify as a gasotransmitter.58 Currently, there are three known members of the
gasotransmitter family – nitric oxide (NO), carbon monoxide (CO) and hydrogen sulfide
(H2S).

Table 1. Criteria for classification of a gasotransmitter
1

They are small molecules of gas, like nitric oxide (NO) carbon monoxide (CO)
and hydrogen sulfide (H2S).

2

They are freely permeable through the membrane and their effects do not depend
on membrane receptors.

3

They are endogenously and enzymatically generated in a regulated manner.

4

They have well-defined specific functions at physiologically relevant
concentrations

5

Their cellular effects may or may not be mediated by second messengers, but
should have specific cellular and molecular targets.

(Modified table from Wang, R.; 2002)
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1.4.1 Nitric oxide and carbon monoxide
The first gaseous molecule to be classified as a gasotransmitter was NO. It was
discovered as an endothelium-derived relaxing factor and macrophage activator.59 It is
produced endogenously during the conversion of L-arginine to L-citruline by the enzyme
nitric oxide synthase (NOS) (Figure 2).60 There are three subtypes of the NOS enzyme –
inducible NOS (iNOS), endothelium NOS (eNOS) and neuronal NOS (nNOS). While the
iNOS is triggered during inflammatory conditions and immune responses, the eNOS and
nNOS are constitutively expressed in the endothelial cell and neuronal/renal macula densa
cells respectively. The physiological role of NO is to modulate platelet aggregation, assist
in leukocyte adhesion and smooth muscle relaxation. However, under conditions of
hypoxia and in the presence of ROS (such as superoxide ions), NO reacts to form
peroxynitrite, which is a strong nitrating oxidant that causes depletion of antioxidants
(such as glutathione) and contributes to the I/R damage.58,60
CO was known to be formed physiologically long before the analysis of its physiological
function.61 During the conversion of heme to biliverdin by the enzyme heme oxygenase
(HO), CO is synthesized by the use of oxygen and energy molecule nicotinamide adenine
dinucleotide phosphate (NADP) (Figure 2). Similar to NOS, there are three subtypes for
HO – HO-1, HO-2 and HO-3. HO-1 is strongly induced under oxidative, chemical and
physical stress in the cortical tubules and renal vasculature; HO-2 is constitutively
expressed in the brain while HO-3 is another spliced version of HO-2.60 At physiological
level and concentrations, CO plays anti-stress and anti-inflammatory roles by suppressing
the production of inflammatory cytokines62, prevents arteriosclerotic lesions63 and
provides cytoprotection by stabilizing hypoxia inducible factor.64
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Figure 2: Endogenous production of NO and CO in cells.
NO is produced from L-arginine yielding L-citrulline, a reaction catalyzed by three
enzymes, nNOS, iNOS and eNOS. The half-life of NO is very short; it is metabolized
within milliseconds. CO is produced from heme by HO-1, HO-2 and HO-3. [Modified
figure from Snijder et al., 2013]
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1.4.2 Hydrogen Sulfide
Hydrogen sulfide has been recently added to the family of gasotransmitters.58 Historically
known for its rotten egg smell and toxicity at higher concentrations, it was not until 1989
that H2S production was detected endogenously.65 A few years later, it was proposed to
be an endogenous neuromodulator due to its capability of enhancing N-methyl-Daspartate (NMDA) receptor mediated responses and induction of long term potentiation in
hippocampus.66 Following these discoveries, it was also observed that H2S has the
capacity to dilate blood vessels in various murine and in-vitro models.67 These
characteristics intrigued research interests in the H2S molecule.
Non-toxic levels of H2S are reported in micromolar quantities as it has been shown to
exist at concentrations of 30μM – 300μM in the vertebrate blood.66,68 In the human body,
at a temperature of 37ºC and pH of 7.4, 80% of H2S exists as a hydrogen sulfite ion
(HS-).69 Most mammals produce endogenous H2S by using three enzymes - cystathionine
gamma lyase (CSE), cystathionine beta synthase and 3-mercaptopyruvate
sulfurtransferase (3MST) [Figure 3]. Cysteine is an essential precursor for all of these
enzymatic pathways.66,70 In the kidneys, all three enzymes are primarily located in the
proximal tubules in the renal cortex. While CBS and CSE are present in the cytosol of the
cells, 3-MST is located in mitochondria as well as cytosol.71 In fact, these enzymes tend
to relocalize to the mitochondria during stress conditions.
Physiologically, the H2S plays an important role in preventing inflammation72, oxidative
stress73, neuromodulation66, vasoregulation74 and inhibition of insulin resistance75. Further
studies in animal models and human disease have shown that defective or less than
optimal endogenous H2S production causes ageing76, cardiovascular diseases77 and
respiratory pathologies like asthma78 and chronic obstructive pulmonary disease.79 In
addition, involvement of H2S in cell functioning, cytoprotection and cellular signaling is
being actively explored.
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Figure 3: Enzymatic pathway for endogenous production of hydrogen sulfide.
H2S is produced by CSE, CBS and 3MST from homocysteine, cystathionine, L-cysteine
and D-cysteine. Cysteine aminotransferase (CAT) and D-amino acid oxidase (DAO) are
required to convert L-cysteine and D-cysteine into 3-mercaptopyruvate (3MP) that is used
as a substrate for H2S production by 3-MST.[Modified from Snijder et al., 2013]
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1.5 Hydrogen sulfide and IRI
Numerous studies using in-vivo and ex-vivo models have demonstrated protective effects
of H2S against IRI in various organ transplant models including that of the lung80, liver81,
heart82,83 and kidney.84,85 The protection rendered by H2S in these studies is related to the
physiological effects of H2S that are discussed in depth in the next section.

1.5.1 Inflammation and H2S
Inflammation is a protective physiological reaction of vascularized tissue to injury and
can be categorized as acute or chronic, depending on the duration and mechanism of the
reaction.86 Acute inflammation is the early host response that results in increased blood
flow (vasodilation) and neutrophil infiltration to the site of injury, while chronic
inflammation is of prolonged duration and may follow acute inflammation.87
H2S plays opposing roles in inflammation. Some studies claim that H2S helps reduce the
inflammatory processes while others show increased inflammation after use of H2S.
However, the crucial fact that plays an important role in determining the impact of H2S on
inflammatory processes is its concentration in that tissue or cell. Time and again, it has
been shown that higher doses of H2S are toxic, pro-inflammatory and cause cell death88
while lower physiological doses render protection from cell death.72,74,82
Some studies have linked the decreased expression of pro-inflammatory molecules as one
of the mechanistic pathways of protective H2S. An in-vivo study has shown a reduction in
expression of tumor necrosis factor-alpha (TNF- α) following supplementation with
H2S.90 TNF- α is a key member of the cytokine family. It plays a role in immune system
during inflammation, cell proliferation, differentiation and apoptosis. 91 Many cell types
produce this factor (T-cells, B-cells, neutrophils, etc.) following a stimulation by other
cytokines or pathophysiological conditions.92 A study on human coronary endothelial
cells has showed that TNF- α indirectly contributes to the ROS production in the sites of
inflammation93 and caspase activation leading to apoptosis. 94 Thus, reduction in TNF- α
can help mitigate some harmful effects of IRI.
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1.5.2 Antioxidant effect
ROS are produced in limited quantities under normal physiological conditions. As a
result, the cells are easily able to detoxify the ROS by using specific enzymes such as
glutathione peroxidase and superoxide dismutase; and other antioxidant molecules like
glutathione and vitamins C & E.95 Glutathione is one of the most effective antioxidants
present in our body. However, when ROS are produced in excess amount during IRI, they
can damage the cell membrane and proteins; activate signaling pathways such as mitogen
activated protein kinases (MAPK) and c-Jun-N-terminal kinase leading to apoptosis.96
H2S has been shown to have direct and indirect antioxidant properties. It acts as a direct
antioxidant by reducing reactive molecules and scavenging ROS radicals and anions.97,98
Indirectly, H2S is known to up-regulate intracellular levels of glutathione and superoxide
dismutase and thereby help in the removal of excessive ROS.83 In-vitro studies by
Whiteman et al. on human neuro-epithelium cells have depicted reduced lipid
peroxidation along with decreased cytotoxic effects of radical and non-radical
intermediates (such as peroxynitrites and lipid hydro-peroxides) on protein nitration and
oxidation upon treatment with H2S.99,100 Another study by Geng et al. also demonstrated
protective effect of H2S on contractile activity of cardiac myocytes in rats by directly
scavenging oxygen free radicals (superoxides and hydrogen peroxides) along with
decreasing the accumulation of lipid peroxidations.101

1.5.3 Protecting mitochondrial integrity and anti-apoptotic role
During oxidative stress conditions, excessively produced ROS and calcium ions
accumulate in the mitochondria as some of the ion channels fail to function properly in
the absence of ATP.50 The hypoxic stress also causes depolarization of the mitochondrial
membrane52 (discussed previously under “IRI effects at cellular level”). The MMPT
eventually causes the breakdown of the mitochondria and the cell can no longer survive
without the energy (ATP) to fuel its metabolism. In-vitro and in-vivo studies have shown
that H2S treatment results in improvement of mitochondrial respiration recovery rate,
increased efficacy of complex I&II and reduced mitochondrial swelling following IRI.83
It also helps to scavenge the ROS present in the mitochondria by up regulating
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glutathione and superoxide dismutase. Overall, H2S protects mitochondrial
degradation/breakdown due to IRI.
Studies have also reported the protective effects of H2S against apoptosis. In a murine
model of oxidative stress related to hemorrhagic shock, Xu et al. demonstrated that H2S
administration protected the lungs by suppressing oxidative stress and apoptotic signaling
pathway along with decreasing the expression of various mitochondria associated and
other apoptotic proteins such as active caspase 3/8, Bax and increased expression of antiapoptotic protein Bcl-2. Another study by Sivarajah et al. showed that H2S is associated
with decreased apoptosis demonstrated by reduction in caspase 9 activity in the cardiac
myocytes subjected to 25 minutes of ischemia and 2 hours of reperfusion in a rat
model.104 Based on these studies, H2S seems to down regulate the proteins associated with
apoptosis while up-regulating the ones that prevent cell damage and death.

1.5.4 H2S donor molecules
H2S exists as a gaseous form of matter. This physical property limits the use of this form
since it would be hard to deliver and maintain accurate dissolved concentration of a gas.
As a result, a variety of H2S donor molecules are being used to study the effects of H2S
supplementation through in-vivo or in-vitro IRI models.
Some of the natural compounds that are most commonly used to deliver H2S in research
setting include salts like sodium hydrogen sulfide or sodium sulfide (NaHS/ Na2S), Lcysteine and D-cysteine. While the crude sulfide salts provide exogenous H2S, the
different isomers of cysteine help with the endogenous production of H2S. L-cysteine has
been long known to contribute to endogenous production of H2S through the use of CBS,
CSE and 3-MST enzymes. D-cysteine has only been recently identified as a novel
pathway for endogenous H2S production via the use of DAO and 3-MST enzymes.
However, the D-cysteine involving pathway is optimal at physiological pH 7.4 and
independent of two pyridoxal 5’-phosphate (PLP) unlike the L-cysteine pathway that
prefers alkaline pH and is PLP dependent. In addition, the D-cysteine has 80 fold greater
H2S producing activity in the kidneys than the L-cysteine.105 Furthermore, the study by
Shibuya et al. has demonstrated more efficient protection against IRI in the renal cortex
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of mice following oral administration of D-cysteine in comparison to L-cysteine.106 This
makes D-cysteine a better choice over L-cysteine for increasing the endogenous
production of H2S.
Although the sulfide salts (NaHS, Na2S) are readily available and convenient to use in
laboratory, Whiteman et al. has listed a few drawbacks associated with the use of these
molecules as H2S donors.107 First of all, salts like NaHS/ Na2S undergo instantaneous
dissociation that generates H2S gas. The rapid dissolution causes a burst of the gas that
could also lead to toxicity in the cell considering the basal plasma levels of H2S in
vertebrates have been reported to be around 30μM to 300μM and the concentration of
sodium sulfide salts used in research studies ranges from high micromolar to millimolar
concentrations. In contrast, the endogenous enzymatic production of H2S is a slow and
sustained process carried out by CBS, CSE and 3-MST.60 Further, the problem of zero
sustainability of H2S release renders the cells susceptible to injury in the subsequent
phases of IRI.
These drawbacks prompted the search for slow releasing H2S donors that could continue
releasing H2S over longer periods of time. This would also help to lessen the chances of
toxicity since only limited amount of H2S is released in a given time. Moore and
colleagues, at the National University of Singapore, developed the first water soluble
slow-releasing H2S donor named as morpholin-4-ium 4 methoxyphenyl(morpholino)
phosphinodithioate (GYY4137).108 The chemical synthesis equation is shown in figure 4
and depicts the molecular structure of the molecule. In their study, it was observed that
GYY4137 takes about 600 seconds to reach its peak rate of release and then maintains the
release rate for over 180 minutes. This particular feature enables it to mimic the biological
conditions where a sustained release of H2S is available to the cells when needed. Also, it
should be noted that every molecule of GYY4137 releases two molecules of H2S and the
decomposition products of this molecule seem to be inactive with no possible effects on
the cells.87 Further, the final concentrations of H2S generated from GYY4137 are more
physiologically, pathophysiologically and therapeutically relevant than those from the
sulfide salts. Lastly, the water solubility of GYY4137 makes it very convenient for use in
laboratory as it can be easily dissolved in water based solvents (cell culture medium as
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well) without requiring specific organic solvents such as the dimethyl sulfoxide
(DMSO).109
A review of literature shows very similar protective effects of GYY4137 as the H2S
molecule. As described previously, H2S plays a role in decreasing oxidative stress and
preserving mitochondrial membrane potential during IRI. Likewise, GYY4137 has been
shown to exert cytoprotective effects in cellular and animal models. For instance, 10μM 200μM dose range of this molecule impedes cytotoxicity induced by H2O2 and
peroxynitrite in human mesenchymal progenitor cells and human articular chondrocytes.
In the same study, it was shown to preserve mitochondrial membrane potential and
inhibited ROS production in the mitochondria.110 Furthermore, a study on human
umbilical vein endothelial cells (HUVEC) substantiated the role played by endogenous
H2S in suppressing the cytotoxicity induced by H2O2 whereby the siRNA-mediated
knockdown of CSE aggravated cellular injury.111 This supports the viable notion of
therapeutic capability for H2S donor molecules.
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Figure 4: Chemical equation for synthesis of GYY4137
Morpholine [20mmol] (dissolved in methyl chloride) was added to of 2,4-bis(4methoxyphenyl)-2,4-dithioxo-1,3,2,4-dithiadiphosphetane [4mmol] (dissolved in methyl
chloride) in the presence of dichloromethane (DCM) at room temperature (RT). (Taken
from Li et al., 2008)
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1.6 Rationale, Hypotheses and Aims
1.6.1 Rationale
Our lab has previously shown that supplementation of organ preservation solution with
H2S leads to significant survival and tissue protection at prolonged periods of cold
ischemic stress (24 hours) followed by subsequent renal transplantation.112 We have also
observed that H2S renders protection against warm renal IRI in a non-transplantation
model of uni-nephrectomised rats involving 1 hour warm ischemia and 2 hours of
reperfusion.90 Although numerous studies have shown the protective effects of H2S
against renal IRI, not a lot has been explored in the field of DCD transplants that involve
a combination of warm and cold ischemia. Through this study, I aimed to assess the
protective effects of H2S supplementation in a murine model of DCD transplantation and
further assess the mechanisms underlying the protective role of H2S in such a model.

1.6.2 Hypotheses
In-vivo
Supplementing donor rats with a precursor H2S molecule and the cold organ preservation
solution (UW) with exogenous H2S would accelerate renal recovery and improve graft
function along with the recipient survival rates.
In-vitro
Addition of synthetic H2S donor molecule during hypoxia to the growth media of porcine
kidney proximal tubular epithelial cells (LLC-PK1) would help attenuate
pathophysiological effects of IRI at cellular level resulting in increased cell viability.

1.6.3 Aims
Aim 1: To compare renal function in the treatment and untreated group recipient rats by
analyzing serum and urine samples
Aim 2: To assess the renal graft obtained at end point or after death of the subject for
apoptosis and glomerular/tubular necrosis using histological staining techniques (TUNEL
stain & H/E stain)
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Aim 3: To measure mRNA expression of various pro-inflammatory (TNF- α), proapoptotic (Bax, Bid) and anti-apoptotic (Bcl-2] mediators
Aim 4: To understand the underlying mechanism for protective effects of H2S using an
in-vitro model
Aim 4.1: Develop a protocol for the in-vitro IRI model
Aim 4.2: Study and quantify effect of GYY4137 on cells exposed to hypoxia and
subsequent reoxygenation by measuring necrosis, late apoptosis and cell viability
Aim 4.3: Assess the effect of H2S supplementation on mitochondrial apoptotic
pathway by measuring changes in ROS, mitochondrial membrane potential and
changes in expression of mitochondria associated apoptotic markers
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Chapter 2

2

Materials and Methods

This section describes the different methods that were used to carry out the experiments
covered under this project. It involved the use of both in-vivo and in-vitro methods.

2.1 Murine Model of Donation after Cardiac Death (DCD)
Renal Transplantation
2.1.1 Animal description and care
Adult male Lewis syngeneic rats (250g – 300g) purchased from Charles River
Laboratories International Limited (USA) were used for this study to prevent any
confounding effects of immunosuppression. The animals were maintained in accordance
with the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory
Animal Resources, National Research Council. The animals were housed at the animal
facility located in the Animal Care and Veterinary Services Department at The University
of Western Ontario. The experimental protocol and housing conditions followed the
guidelines of the Council on Animal Care of the institution.

2.1.2 Preliminary experiments and final experimental design
The rats were randomly divided into one of the following three groups: sham, untreated or
treatment. The sham group rats underwent a midline incision and the procedure did not
involve kidney transplantation. On the other hand, the untreated and the treatment group
rats received the donor kidneys that had experienced a combination of warm and cold
ischemic injury.
To decide the time intervals for warm and cold ischemia, some preliminary experiments
were carried out. In the beginning, prolonged warm (45 minutes) and cold ischemic (18
hours) times were used to maximize the amount of injury and to see a better difference
between the untreated and treatment groups. However, the recipient rats were unable to
survive past post-operative day two in both the groups. Thereafter, the warm ischemic
injury time was lowered to 20 minutes while maintaining the same cold ischemic time so
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as to make sure the grafts retained their function in the recipient. Due to the reduced
injury to the donor kidney, the rats in both groups survived until the end point of 30 days.
The serum creatinine levels showed slight differences between the untreated and the
treatment group such that there was a faster recovery of renal function in the treatment
group (Appendix A). However, the warm ischemia time did not appear to cause
significant injury to the grafts as both the treatment and the untreated group recipients
were able to recover from the induced injuries and survived until the end point.
In the finalized experimental design (shown in Figure 5), the warm ischemic time was
increased to 30 minutes and the cold ischemic time was 18 hours so as to cause sufficient
damage to observe significant differences between the different experimental groups. The
untreated and treatment group rats received the donor kidneys that had undergone
clamping for 30 minutes and a cold storage period of 18 hours in the standard organ
preservation solution called University of Wisconsin (UW) solution. The main differences
between the untreated and the treatment group included injecting the donor rats with Dcysteine prior to the surgical procedure and supplementing the organ storage and flush
solution with hydrogen sulfide (H2S) as detailed in section 2.1.3.

2.1.3 Surgical procedure
The donor rats for the treatment group received an intraperitoneal (I.P.) injection of Dcysteine (purchased from Sigma Aldrich Company, USA) dissolved in 0.5mL of sterile
saline solution (0.9%NaCl) at a concentration of 2mmol/kg rat weight at least one hour
prior to the clamping of the pedicle. The dosage and timing for D-cysteine injection was
based on a study by Shibuya et al. where he orally administered D-cysteine at a dose of
8mmol/kg of the body weight of mice and observed increased concentrations of H2S in
those mice for up to 3 hours following ingestion.106 Taking into account the lower
gastrointestinal absorption of the ingested drug, the donor rats were injected
intraperitoneally with D-cysteine at 4mmol/kg body weight in our pilot experiment.
However, none of the treatment rats survived in that experiment. Therefore, the dosage of
D-cysteine was reduced to half that amount (2mmol/kg of rat weight) in our preliminary
experiments and the treatment rats were able to survive following renal transplantation.
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The rats were anesthetized by intramuscular injection of 0.2ml ketamine/xylazine and
maintained under anesthesia with 2% isoflurane during surgery. In donor rats, the left
renal pedicle was occluded via atraumatic clamping for 30 minutes to induce warm
ischemia. The left kidney was then flushed with 5mL of UW solution and procured.
Following procurement, it was stored in 50mL of the same solution at 4ºC for 18 hours to
encounter cold ischemia. However, the UW flush and storage solution was supplemented
with 150μM NaHS (sodium hydrogen sulfide) for the treatment group. The same dose
(150μM NaHS) was also used in our other in-vivo IRI study in a rat model that involved
extended periods of cold ischemic stress and showed beneficial effects.
The recipient syngeneic Lewis rats underwent bilateral nephrectomy followed by renal
transplantation of the left kidney procured from the donor. Each surgery was performed
by the same experienced micro-surgeon (Dr. Jifu Jiang, Microsurgeon, Matthew Mailing
Centre for Translational and Transplantation studies) who was blinded to the treatment
group. The length of the surgery/operating time was similar for the untreated and the
treatment group.

2.1.4 Post-operative monitoring
The recipient animals were monitored for a period of 30 days or until the time of death
(whichever came first). Daily health records were maintained for these animals. No
surgical complications were caused by the anastomoses that were carefully examined at
the time of death or sacrifice. Blood and urine samples were obtained from these rats on
post-operative days 3,5,10,20 and 30. The rats were placed in metabolic cages to collect
urine while the blood samples (500μL) were taken from the tail vein. The blood was
centrifuged at 12,000g for 5 minutes to separate the serum. The serum and urine samples
were then stored at -20ºC for later analysis.

2.1.5 Assessment of graft renal function and injury
Serum obtained from the blood samples was analyzed at Core Pathology Laboratories
(University Hospital, London Health Sciences Centre) for creatinine, urea and osmolality.
The urine samples were also examined for creatinine and protein at the same lab facility.
The creatinine and protein values from the urine samples were used to calculate the urine

26

protein-creatinine ratio (adjusted to the rat weight) as an indication of any prevalent signs
of proteinuria in the recipients. The urine osmolality was measured in the lab using The
Advanced® Micro-Osmometer Model 3320 (Advanced Instruments Inc., Massachusetts,
USA). Basically, 20μL of the sample was loaded into the sampler tip of the plunger and
then inserted into the sample port. The test was run for approximately one minute and the
readings were collected. In case of multiple samples being tested on the same day, sample
port was cleaned properly before switching between samples. Also the first readings for
the successive samples, following the first sample, were discarded and the second reading
was recorded to prevent any errors due to sample contamination.

2.1.6 Renal histopathology
At the time of death or sacrifice, the kidney grafts were removed and bivalved sagitally
such that one half was stored at -80ºC and used for qRT-PCR analysis while the other half
was used for histological staining. The tissues were fixed in 10% formalin and sent to the
Molecular Pathology Core Facility (Robarts Research Institute, London, Canada) for
processing. The tissues were embedded, sectioned (8μm width) and stained with
hematoxylin and eosin (H&E) to detect any signs of necrosis. All H&E sections were
analyzed and quantified by an experienced clinical renal pathologist (Dr. Aaron Haig,
London Health Sciences Centre) who was blinded to the treatment assignments. The
slides were scored for acute tubular necrosis (ATN) on a scale of 0-5; where 0 represents
absence, 1 denotes involvement of 1%-10% of glomeruli or cortical area, 2 is 11% - 25%,
3 is 26% - 45%, 4 is 46% - 75% and 5 is greater than 75%.
The histological sections also underwent terminal deoxynucleotidyl-transferase-mediated
dUTP nick end labeling (TUNEL) to determine the level of apoptosis. All slides were
analyzed by taking five pictures of random slide sections per sample using Nixon
microscope at 10X magnification. The injury in the images was assessed using Image-J
software by formulating a macro to precisely identify the dark stained cells in the slides.
The total cell count for each picture was recorded and the median (from five pictures) was
used to denote each sample.
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2.1.7 RNA isolation, cDNA synthesis and real time PCR
The rats that had either died or were sacrificed by post-operative day 3 for each of the
sham, untreated and treatment groups were used to look at relative mRNA expression
levels for certain inflammation and apoptosis related genes. A small part of renal tissue
(containing both the cortex and medulla) measuring one gram in mass was cut from the
sagitally bivalved kidney stored at -80ºC. It was thawed and immediately homogenized
using a mechanical homogenizer and simultaneously adding cell disruption buffer
(provided in the PARIS kit). The homogenate was placed on ice the whole time
(including the time when it was being homogenized) to prevent any degradation of the
mRNA or proteins. The total RNA content was isolated from the homogenate using
Protein and RNA (PARIS) Isolation kit (life technologies, USA) as per the
manufacturer’s protocol. Briefly, equal volumes (200μL) of cell lysis buffer (PARIS kit)
and 100% ethanol were added to 200μL of tissue homogenate. The entire mixture
(600μL) was centrifuged at 12000xg for 1-2 minutes in a collection tube with filter. The
filtrate was discarded and the filter was washed sequentially with wash buffer 1 (one
time) and wash buffer 2/3 (two times). The mRNA was recovered using the elution buffer
(heated to 95ºC) with two sequential dilutions of 40μL and 10μL. All the buffers were
provided with the PARIS kit. For reverse transcription, 4μL of SuperScript VILO™
MasterMix (Invitrogen) was added to about 400ng of mRNA and the sample volume was
normalized to 20μL by addition of DEPC treated water (0.1% DEPC). The sample tubes
were then placed in the Eppendorf thermal cycler set to the following cycles: 25ºC (10
minutes), 42ºC (60 minutes) and 85ºC (5 minutes). After completion of the cycles, the
cDNA samples were stored at 4ºC. The concentration and quality of the isolated mRNA
and cDNA were analyzed using NanoDrop 2000. The A260/280 readings for the isolated
mRNA and cDNA were consistently greater than 1.8 indicating little to no contamination.
For qPCR, each sample used 2x SensiFAST SYBR Hi-ROX Mix (BIOLINE) and had a
total volume of 20μL containing 20ng of respective cDNA. The forward and the reverse
primer sequences were generated using the NCBI database and the IDT primer quest tool.
The primers were ordered from Sigma Aldrich and the primer sequences are provided in
table 3. The target gene signals were normalized against β-actin. All qRT-PCR assays
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were performed using BIO-RAD thermal cycler and software package and the results were
analyzed using Graph pad prism 6.

2.1.8 Data analysis
The data were analyzed using the Graph Pad prism 6 software. All statistical analyses
involved use of either one-way or two-way ANOVA (with multiple comparisons) or
Student’s t-tests (multiple) as required and the survival analysis was done using the
Kaplan-Meier method. Statistical significance was accepted at p < 0.05 with a confidence
interval of 95%. The values reported in results section (all figures) are mean ± standard
error mean (SEM) unless otherwise stated.
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Figure 5: Finalized experimental design for in-vivo murine model of DCD renal
transplantation
The figure shows three experimental groups – the treatment group (red), the untreated
group (green) and the sham-operated (blue). The sham group rats only undergo a midline
incision. In untreated and treatment groups, the donor rat’s kidney pedicle is clamped for
30 minutes (warm ischemia) and then stored at 4ºC (cold storage/ischemia) for 18 hours.
D-cysteine is injected intraperitoneally one hour prior to ischemic injury in donor rats and
150 NaHS is added to UW solution only for the treatment group. The recipient rats
undergo bilateral nephrectomy prior to the transplantation of the renal grafts and are
monitored until the end point (30 days) or the time of death, whichever comes first.

30

Table 2. Primer sequences (rat) used in qRT-PCR reactions
S. No.
1.

2.

3.

4.

5.

6.

Gene

Sequence 5’  3’

B-actin forward

GTGTGGATTGGTGGCTCTATC

B-actin Reverse

CAGTCCGCCTAGAAGCATTT

BAX Forward

TGCTACAGGGTTTCATCCAG

BAX Reverse

GACACTCGCTCAGCTTCTT

BID Forward

CGATACGGCAAGAATTGTGAAG

BID Reverse

ATTCCCACCACCTGGAAATAG

Caspase-3 Forward

CCACGGAATTTGAGTCCTTCT

Caspase-3 Reverse

CCACTCCCAGTCATTCCTTTAG

BCL-2 Forward

GTGGATGACTGAGTACCTGAAC

BCL-2 Reverse

GAGACAGCCAGGAGAAATCAA

TNFα Forward

GCAGATGGGCTGTACCTTATC

TNF-α Reverse

GAAATGGCAAATCGGCTGAC
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2.2 DCD model in LLC-PK1 cells
2.2.1 LLC-PK1 cell line
The proximal tubular epithelial pig kidney cell line (LLC-PK1) was used for the in-vitro
experiments. These cells were obtained in a frozen vial from the American Type Culture
Collection (ATCC, Rockville, MD, USA). The cells were cultured in 75cm2 flasks in a
carbon-dioxide incubator (5%CO2) at 37ºC using Medium199 (M199; Life Technologies
Inc., USA) that contained penicillin (100 U/mL), streptomycin (100 U/mL) and was
supplemented with 10% heat-inactivated fetal bovine serum (FBS; Hyclone, Logan,
USA). The cells were sub-cultured and plated onto twelve well plates upon reaching 80%
- 90% confluence.

2.2.2 Synthetic hydrogen sulfide donor used
For the in-vitro experiments involving hypoxic injury, slow releasing synthetic hydrogen
sulfide donor GYY4137 (courtesy of Dr. Matthew Whiteman from Exeter Medical
School, England) was used to study the mechanism of hydrogen sulfide protection at a
cellular level. Studies have shown that it reaches its peak rate of release approximately
600s later than sodium hydrogen sulfide. Also, this molecule tends to maintain its peak
release rate over a longer period of time rather than an initial burst observed in case of
sodium hydrogen sulfide salts.

2.2.3 Experimental design
For all in-vitro experiments, 2x105 cells suspended in 1mL of Medium199 (10%FBS, 1%
Penicillin/Streptomycin) were plated in each well in the 12-well plate and allowed to
grow in the carbon-dioxide incubator for 36 hours. During the experimental conditions,
Dulbecco’s Modified Eagle’s Medium (DMEM; without any glucose or FBS) was used to
restrict the supply of nutrients to the cells. Upon reaching 80% - 90% confluence,
hydrogen sulfide donor molecule (GYY4137) dissolved in DMEM at varying
concentrations (500nM – 500μM) was added to the wells. The plates were then placed in
the hypoxia chamber (H85 Whitley hypoxy-station) set to 1% oxygen, 5% carbon dioxide
and 94% nitrogen thereby limiting oxygen supply to mimic the conditions experienced
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during ischemic injury. For warm conditions, the temperature of the hypoxia chamber
was set to 37ºC while for the cold conditions the lowest internal temperature achieved in
the chamber was 7ºC – 8ºC and the 12 well plates had to be placed on ice packs to reach
temperature of 4ºC. A thermometer was placed beside the plates on the ice pack to verify
the temperature experienced by the cells.
In the beginning, a number of trials were conducted to finalise a combination of warm
and cold hypoxic interval that would cause enough damage to the cells thereby lowering
their viability by at least 40% - 50%, but at the same time the damage caused had to be
reversible such that the cells could be rescued from that damage with the treatments being
provided. These combination times included 3 hours warm + 3 hours cold, 3 hours warm
+ 9 hours cold, 4 hours warm + 6 hours cold and 4 hours warm + 8 hours cold (Figure
12). In all these combination experiments, it was observed that the ischemic injury (as
measured by the percentage of viable cells) did not change by a large extent with the
increases in the cold hypoxic time but depicted some change when the warm hypoxic
time was increased. In order to see a significant difference in rescue, the hypoxic time
was further increased and the percentages of viable cells were compared between the
following hypoxic treatments: 12 hours warm + 24 hours cold and 12 hours warm (only).
Based on the results (as described in the result section), the future experiments were
conducted with the 12 hours of warm hypoxic time.

2.2.4 Viability analysis
After experiencing 12 hours of warm hypoxic time, the 12 well plates were taken out of
the hypoxia chamber. The DMEM (media) from the wells was centrifuged at 500 x g for
5 minutes to collect any floaters or dead cells in it. These dead cells were suspended in
1mL of Medium199 (1% penicillin/streptomycin and 10% FBS) and re-added to the same
wells. The plates were placed in the carbon-dioxide incubator (at 37ºC, 5%CO2) for 24
hours allowing reoxygenation and associated injury.
Following reoxygenation, the cell samples were analyzed for the percentage of viable
cells. Briefly, the reoxygenation media was collected in labeled flow tubes. The wells
were washed with 1X phosphate buffered saline (PBS) solution to remove any traces of
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FBS in the wells and 100μL of 0.25% trypsin (Gibco, Life technologies, USA) was added
to each well to lift the monolayer of cells. The plates containing trypsin were incubated at
37ºC for 3-6 minutes to accelerate the process. Following incubation, 500μL of
medium199 (1%Penicillin/Streptomycin, 10%FBS) was added to the wells to inactivate
the trypsin and the medium (now containing the trypsinized cells) was collected in the
same flow tubes. Two samples of heat-killed cells (65ºC, 10 minutes) were used as
positive control for the stains. The flow tubes were then centrifuged at 600 x g for 6
minutes to get a rigid pellet of cells at the bottom. The supernatant was removed and the
cells were washed with 1X-PBS two times by re-suspension and centrifugation. The final
pellet of cells was suspended in 100μL of Annexin-V binding buffer (Biology Legend,
USA). Following suspension, 1μL of PE conjugated Annexin-V (Biology Legend, USA)
and 3μL of 7- Aminoactinomycin-D (7-AAD; Bio Legend, USA) stains were added to
each tube and allowed to incubate in dark for 15 minutes. The stained samples were then
analyzed using the Beckman Coulter FC 500 flow cytometer (Beckman Coulter Canada,
ON). Two channels, FL2 with 572BP filter for PE conjugated Annexin-V and FL4 with
675 BP filter for detecting 7-AAD, were used to assess the viability of cell samples.

2.2.5 Quantification of reactive oxygen species
The amount of reactive oxygen species was also quantified in the treatments. Briefly, the
treatment group (DMEM only, DMEM with 50μM GYY4137) plate was taken out from
the hypoxia chamber. The DMEM (cell media) was collected in labeled flow tubes and
the wells were re-perfused in medium199 (no phenol red, 10%FBS, 1% P/S) for half an
hour in the incubator. Following the re-perfusion, the cells were trypsinized and cell pellet
collected using the same procedure and steps used for viability analysis. For the positive
control, the cells were suspended in 500μL of 1XPBS containing 3% hydrogen peroxide
(H2O2) for about 10 minutes prior to the collection of cell pellet. The cell pellets were
then suspended in 100μL of 1X-PBS and 2μL of 1mM stock dihydrorhodamine 123
(DHR 123, Life technologies, USA) stain was added to each flow tube. The tubes were
incubated in the dark for about 15 minutes before being analyzed in the flow cytometer
(Beckman Coulter) using FL1 channel.
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2.2.6 Detection of mitochondrial membrane depolarization
The cell samples were also analyzed for changes in the mitochondrial membrane
permeability by using the stain JC-1 (Invitrogen, Life Technologies) for flow cytometry.
Following the hypoxic injury (12 hours warm in hypoxia chamber), the media from the
wells was collected in the centrifuge tubes and the wells were washed with 1X PBS to
remove any traces of media. The cells were then trypsinized (with 0.25% trypsin and 3-5
minutes incubation) and 500μL of medium199 (1%Penicillin/Streptomycin, 10%FBS)
was added to the wells to inactivate the trypsin. The medium containing the trypsinized
cells was collected in the same flow tubes. A sample of heat-killed cells (65ºC, 10
minutes) was used as a positive control for the stain. The flow tubes were centrifuged at
600 x g for 6 minutes to get a rigid pellet of cells at the bottom. The supernatant was
removed and the cells were washed with 1X-PBS two times by re-suspension and
centrifugation. The final pellet of cells was suspended in 100μL of medium199 and 1μL
of JC-1 stain was added to the tubes. The tubes were then placed in the carbon dioxide
incubator at 37ºC for 15 minutes and analyzed using the FL1 channel on flow cytometer.

2.2.7 Measuring mRNA expression of apoptosis related proteins
The total RNA content was isolated from the cells following 15 minutes of reoxygenation
with M199 media after 12 hours of warm hypoxia. The wells were washed with 1X PBS
twice to remove any traces of media. About 1mL of Ribozol® was added to the each well
and allowed to sit for 4-5 minutes. The cell homogenate was passed through the pipette
tip 3 times before collecting it in an eppendorf tube. The mRNA was extracted from the
homogenate using the Pure Link® RNA Mini Kit (ambion® by Life Technologies, USA).
Briefly 700μL of 70% ethanol was added to each tube and centrifuged in the spin
cartridge at 12000xg for 15 seconds. The filtrate was discarded and the filter was washed
sequentially with wash buffer 1 (one time) and wash buffer 2/3 (two times). The mRNA
was finally recovered using the 30μL of RNAase-free water. All the buffers were
provided with the kit. For reverse transcription, 4μL of SuperScript VILO™ MasterMix
(Invitrogen) was added to about 300ng of mRNA and the sample volume was normalized
to 20μL by addition of DEPC (0.1%) treated water. The sample tubes were then placed in
the Eppendorf thermal cycler set to the following cycles: 25ºC (10 minutes), 42ºC (60
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minutes) and 85ºC (5 minutes). After completion of the cycles, the cDNA samples were
stored at 4ºC. The concentrations of the isolated mRNA and cDNA were measured using
nanodrop. The A260/280 readings for the isolated mRNA and cDNA were consistently
greater than 1.8 indicating little to no contamination.
For qPCR, each sample used 2x SensiFAST SYBR Hi-ROX Mix (BIOLINE) and had a
total volume of 20μL containing 20ng of respective cDNA. The forward and the reverse
primer sequences were generated using the NCBI database and the IDT primer quest tool.
The primers were ordered from Sigma Aldrich and the primer sequences are provided in
table 4. The target gene signals were normalized against β-actin. All qRT-PCR assays
were performed using BIO-RAD thermal cycler and software package and the results were
analyzed using Graph pad prism 6.

2.2.8 Data analysis
The data were analyzed using the Graph Pad prism 6 software. All statistical analyses
involve use of either one-way or two-way ANOVA (with multiple comparisons) or
Student’s t-test as required. Statistical significance was accepted at p < 0.05 or lower with
a confidence interval of at least 95% or higher depending on the p-value. The values
reported in results section (all figures) are mean ± standard error mean (SEM) unless
otherwise stated.
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Table 3. Primer sequences for qRT-PCR in LLC-PK1 cell samples
S. No.
1.

2.

3.

5.

6.

7.

Gene

Sequence 5’  3’

B-actin forward

TCTGGCACCACACCTTCTA

B-actin Reverse

TCTTCTCACGGTTGGCTTTG

BAX Forward

CCCTTTTGCTTCAGGGGATGA

BAX Reverse

CCGCCACTCGGAAAAAGACT

BID Forward

GGATTCTAAGGTCAGCAACGGT

BID Reverse

GGATTCTAAGGTCAGCAACGGT

BCL-2 Forward

AGGATAACGGAGGCTGGGATG

BCL-2 reverse

AGGATAACGGAGGCTGGGATG

MCL-1 Forward

CTAGAAGGCGGCATCAGAAA

MCL-1 Reverse

GTGGCTGGAGTTGGTTAAGA

EDN-1 Forward

CTGCACTCCGCCTAAAGTATT

EDN-1 Reverse

GATTTCCACGAGGCTAGGATTT
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Chapter 3

3

Results

The objective of our study was to evaluate the role of H2S supplementation in attenuating
the effects of IRI in an in-vivo murine model of donation after cardiac death and study the
underlying mechanisms in an in-vitro model of IRI using porcine proximal tubular
epithelial kidney cells. The results from the current study are explained in the next
sections.

3.1 Murine Model of Donation after Cardiac Death
The sham-operated rats underwent a midline incision only while the untreated and the
treatment group rats received the donor kidneys that had experienced 30 minutes of warm
ischemia (clamping) and 18 hours of cold storage in either UW solution alone or UW
supplemented with 150μM NaHS respectively. The treatment group donor rats had also
received 2mmol/kg D-cysteine I.P. one hour prior to the clamping of the pedicle. This invivo murine model assesses the effect of H2S supplementation on recipient survival, graft
function and renal injury by analyzing blood serum, urine and renal graft tissue samples
and the results are described below.

3.1.1 Increased survival in treatment group rats
Following renal transplantation, the rats were observed for 30 days. Each group
(untreated – cold storage in UW only; treatment – donors received 2mmol/kg D-cysteine
I.P. and cold storage in UW +150μM NaHS; and sham – no renal transplant) contained
six rats and the sham rats depicted a 100% survival showing efficiency of the surgical
technique. Three out of six untreated group rats died on post-operative day 1,2 and 9
respectively. The other three rats from the untreated group survived till the end point (day
30). However, only one treatment rat died on post-operative day 2 while the rest were
sacrificed upon reaching the end point. Overall, the treatment group rats showed an
increased survival percentage in comparison to the control rats (Figure 6). A significant
difference was observed between the survival curves of the three groups (p< 0.05)
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indicating a trend between the groups as per the log rank test for trend used for survival
curve analysis.

3.1.2 Serum analysis indicates a trend of improved graft function in
treatment group
The serum samples collected from the blood of renal transplant recipients (untreated &
treatment group) and sham-operated rats were analyzed for various parameters such as
serum creatinine, urea and osmolality to compare the renal graft function among the
different experimental groups.
The serum creatinine values indicate a trend depicting much faster and consistent
recovery in the treatment group (Figure 7). The creatinine values decrease rapidly and
approach the sham baseline levels by post-operative day 10 in the treatment group rats.
However, for the untreated rats, the creatinine levels show a comparably slow recovery
during the initial period following transplantation. One should also keep in mind that half
of the untreated group rats that were not doing well were dead by postoperative day 9. As
a result, the serum creatinine values for the untreated group rats that did survive the initial
vulnerable period were very close to the sham levels.
The serum urea and osmolality levels were also measured and are shown in figures 8 (A)
& 8(B), respectively. The serum urea levels followed the same pattern like the serum
creatinine (as expected) since both of them mark the ability of the kidneys to remove
waste products from the body. The osmolality levels remained consistent among the rats
throughout the experimental period indicating normal physiological functioning in these
animals.
Although there is a trend showing reduction in delayed graft function among the
treatment group rats, no statistically significant differences were observed between the
untreated and the treatment group rats in terms of the creatinine, urea and osmolality
measured in blood serum on any post – operative day.
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3.1.3 Urine analysis demonstrates reduced injury in treatment group
The urine collected from the rats on day 3, 5, 10, 20 and 30 was analyzed by measuring
the amount of protein and creatinine in the urine. These values were then used to calculate
the protein to creatinine ratio, which is an indicator of injury to the renal graft. It was
observed that the transplant recipient rats had higher ratio in comparison to the shamoperated rats as expected (Figure 9). Upon statistical analysis using two-way ANOVA
with multiple comparisons, statistically significant difference was observed between the
untreated and the treatment group rats on post-operative day 5 (p<0.05) with a higher
protein to creatinine ratio in the untreated rats in comparison to the treatment group.
The urine osmolality was also measured in these samples and is shown in figure 10. The
urine osmolality in the transplant recipients (both untreated and treatment groups) was
observed to be significantly lower (** = p<0.01, *** = p<0.001, **** = p<0.0001) than
the sham group rats using two-way ANOVA with Tukey’s multiple comparisons test.
Over the time period of 30 days, the osmolality values did seem to increase at a steady
rate for both the untreated and the treatment group rats. However, the values did not reach
the baseline levels within this time period.

3.1.4 ATN scores depict higher histological injury in untreated rats
The scores from the H&E slides scored by the pathologist blinded to the treatment groups
are shown in figure 11. The sham group rats did not show any histological injury as
indicated by the consistent score of ‘0’ across all five rats. The untreated group rats
showed a wider range of injury scores. However, the untreated group rats that were
sacrificed on post-operative day 3 showed significantly higher injury score than the shamoperated rats (* = p<0.05 using two-way ANOVA with Tukey’s multiple comparisons
test). In addition, the treatment group rats scored lower on the injury scale and no
statistically significant difference was observed between the sham operated and treatment
group rats.

40

3.1.5 Comparable amount of apoptosis observed in the untreated and
treatment group renal transplant recipients
Using the TUNEL stain, the tissue samples collected from different experimental groups
on post-operative day 30 were evaluated for the amount of apoptosis in them. The images
of the TUNEL stain slides upon analysis with image-J software did not show any
statistically significant differences between the untreated and the treatment group rats
(Figure 12).

3.1.6 Trends in mRNA expression of pro-apoptotic, anti-apoptotic and
inflammatory markers in the collected tissue
The results from qRT-PCR depicted some trends in the expression levels of various
apoptosis related genes (Figure 13). Although no statistically significant differences were
observed, mRNA analysis indicated a trend towards reduced expression of pro-apoptotic
genes (such as caspase-3, Bax and Bid) and pro-inflammatory gene (TNF-α) in the
treatment group tissue samples (n=4) and increase in the anti-apoptotic marker Bcl-2 in
both the untreated and treatment groups.
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Figure 6: D-Cysteine and H2S supplementation improved survival of renal
transplant recipients.
The graph shows the survival rates of sham-operated rats and renal graft recipients from
the treatment and untreated group rats. The donor rats for the treatment group were
injected I.P. with D-cysteine (2mmol/kg) and the donor kidneys were perfused and stored
in UW solution supplemented with 150μM NaHS. The donor kidneys for the untreated
group were perfused and stored in UW solution alone (n = 6 in each group; * = p < 0.05
as per the log rank test for trend among survival curves).
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Figure 7: D-Cysteine and H2S supplementation indicates a trend of accelerated
recovery in renal graft function following ischemic injury to the renal grafts
The graph shows the levels of serum creatinine in the sham-operated rats and renal graft
recipients from the untreated and treatment groups on post-operative day 3, 10, 20 and 30.
The donor rats for the treatment group were injected I.P. with D-cysteine (2mmol/kg) and
the donor kidneys were perfused and stored in UW solution supplemented with 150μM
NaHS. The donor kidneys for the untreated group were perfused and stored in UW
solution alone (Values are Mean ± SEM, n = 6 in each group but varies for different days
because of variation in survival; differences statistically not significant).
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Figure 8: (A) Serum urea levels depict similar trends as serum creatinine and (B)
serum osmolality remains consistent across different experimental groups over the
time course of experiment
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The graphs show the levels of serum urea and osmolality in the sham-operated rats and
renal graft recipients from the untreated and treatment group on post-operative day 3, 10,
20 and 30. The donor rats for the treatment group were injected I.P. with D-cysteine
(2mmol/kg) and the donor kidneys were perfused and stored in UW solution
supplemented with 150μM NaHS. The donor kidneys for the untreated group were
perfused and stored in UW solution alone. (Values are Mean ± SEM, n = 6 total in each
group but varies for each day depending on survival as per the experimental group;
differences between untreated and treatment groups not significant statistically)
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Figure 9: Urine protein to creatinine ratio indicating inferior kidney function in the
untreated group rats in comparison to the treatment group rats
The graph depicts urine protein to urine creatinine ratio in the sham-operated rats and
renal graft recipient rats from the untreated and treatment group on post-operative days 3,
5, 10, 20 and 30. H2S supplementation in the treatment rats provided some protection
against ischemia reperfusion injury lowering the ratio. A significant difference (p<0.05)
in the ratio was observed between the untreated and the treatment group on post-operative
day 5. (n=3 in untreated and treatment group; n=5 in sham operated group; * = p < 0.05
using two-way ANOVA with Tukey’s multiple comparisons test)
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Figure 10: Decreased urine osmolality in the renal transplant recipients in
comparison to the sham-operated rats
The graphs show urine osmolality in the sham-operated rats and renal graft recipient rats
from the untreated and treatment group on post-operative day 3, 5,10, 20 and 30. The
donor rats for the treatment group were injected I.P. with D-cysteine (2mmol/kg) and the
donor kidneys were perfused and stored in UW solution supplemented with 150μM
NaHS. The donor kidneys for the untreated group were perfused and stored in UW
solution alone. The urine osmolality is significantly lower in the renal transplant
recipients in comparison to the sham-operated rats. (Values are Mean ± SEM, n=3 in
untreated and treatment groups; n=5 in sham operated group,** = p<0.01, *** = p<0.001,
**** = p<0.0001 using two-way ANOVA with Tukey’s multiple comparisons test)

47

Acute Tubular Necrosis Score

5

*

4

Sham
Untreated
Treatment

3
2
1
0

30
ay
D

D

ay

3

-1

Figure 11: H2S supplementation reduces tissue injury following ischemia
reperfusion injury
The H&E tissue slides scored by the pathologist blinded to the treatment groups showed
significant (p<0.05) difference in the acute tubular necrosis scores for the untreated group
and the sham operated rats that were sacrificed on post-operative day 3 depicting higher
injury in the untreated rats. No significant differences observed between the experimental
groups from the tissues collected on post-operative day 30 (* = p<0.05 using two-way
ANOVA with Tukey’s test for multiple comparisons).
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Figure 12: Number of apoptotic cells in kidney tissue collected from untreated group
and treatment group of rats on post operative day 30.
Image of TUNEL stained tissue sections from untreated group (A) and treatment group
(B) at 10X magnification. The scatter plot (C) shows the number of median apoptotic
cells in the graft samples from the two groups counted using the Image-J software. The
subjects shown above had survived until the end point of post-operative day 30.
(Differences between the untreated and treatment group were not statistically significant)
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Figure 13: Differences in the mRNA expression of various apoptosis related genes.
A trend indicating some down-regulation in the expression of pro-apoptotic and
inflammatory markers (Caspase-3, Bid and TNF-α) was observed in the treatment group
while the Bax expression remained at the basal level (as in sham group). The untreated
group depicted a trend towards increased expression of Caspase-3 and Bax that feed the
apoptosis-signaling cascade. However, no statistically significant differences were
observed. (Values are Mean ± SEM, n=4 in untreated and treatment group; n=2 in shamoperated group)
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3.2 In-vitro DCD Model
For the in-vitro aspect of this project, the porcine proximal tubular epithelial kidney cells
were exposed to hypoxic injury in a serum and glucose deprived media and any changes
in cell viability (following 24 hour reoxygenation), quantities of ROS and mitochondrial
membrane potential were measured using the stains Annexin-V/ 7-AAD, DHR 123 and
JC-1 with flow cytometry respectively. These changes were then compared to the cell
samples treated with H2S donor GYY4137 (50μM). We also looked at the m-RNA
expression of apoptosis and injury related marker proteins in our treated and untreated
cell samples using qRT-PCR.
Preliminary experiments helped us to choose the time interval for inducing adequate
hypoxic injury to LLC-PK1 cells. As shown in figure 14, the increases in cold hypoxic
time from 4hours warm + 6hours cold to 4hours warm + 8hours cold does not impact the
cell viability and the mean viability of hypoxic samples stays around 65%. In addition,
the amount of cell death in 12hours warm + 24 hours cold hypoxic time is comparable to
the 12 hours warm alone hypoxia as in both these cases the cell viability goes down by
35%.

3.2.1 GYY4137 improved cell viability and decreased necrosis and
late apoptosis in LLC-PK1 cells experiencing IRI
The dose response curve for GYY4137 showed the protective effects of H2S
supplementation on cell viability. The flow analysis scatter plots and bar graph (Figures
15 and16, respectively) show that the cell viability increases by almost 25% with 50μM
and 500μM doses of GYY4137. The percentage of viable cells in untreated (DMEM)
samples was 51% while it increased to ~ 74% in cell samples treated with H2S donor
(DMEM + 50μM/500μM GYY4137). There was a statistically significant difference
(p<0.05, two way ANOVA with Tukeys test for multiple comparisons) observed between
the percentages of viable cells in the untreated (DMEM with no GYY4137) and treated
(DMEM + 50 μM GYY4137) cell samples.
Some difference was also observed in the amount of necrotic and late-apoptotic cells
while little to no early apoptosis was detected (Figure 17). The percentage of necrotic
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cells decreased from 39% in untreated cells to approximately 20% in the cells treated with
50μM and 500μM of GYY4137. A similar decline was observed in the percentage of late
apoptotic cells from 9% in untreated samples to 4.5% with the same concentrations of
GYY4137. However, the differences between percentages of necrotic and late-apoptotic
cells in the treated and untreated samples were not found to be statistically significant and
the experiment would need to be repeated in order to discover statistically significant
differences.

3.2.2 GYY4137 supplementation indicated a trend in reduction of
cells with detectable ROS
A trend indicating reduction in the percentage of cells with reactive oxygen molecules is
evident in figure 18. Although the differences are not statistically significant and further
experiments would be needed to increase the number of samples for finding statistically
significant differences, but the current trend in results looks promising as the exogenous
supplementation with H2S donor helped decrease the amount of cells with detectable
ROS. Under normoxic conditions, the percentage of healthy cells (Media) with ROS is
around 8%. When these cells are deprived of FBS and glucose, the percentage of cells
with ROS goes up to 22% at normal oxygen concentrations. The same glucose/FBS
deficient conditions under hypoxia increase the percentage of cells with ROS to 40%.
However, addition of 50μM GYY4137 reduces the ROS and thereby lowers the
percentage of cells with detectable ROS to 33%.

3.2.3 Trend depicting decline in depolarization of the mitochondrial
membrane in cells treated with GYY4137
Supplementation with exogenous H2S donor also helped decrease the percentage of cells
with depolarized mitochondrial membrane as shown by the trend observed in figure 19.
The untreated cell samples showed approximately 13% of cells with depolarized
mitochondria. Upon treatment with 50μM GYY4137, the percentage of cells with
depolarized mitochondrial membrane decreased to about 10% indicating a role played by
H2S in mitochondrial membrane permeability transition. However, no significant
differences were observed between the treated and the untreated cell samples and a higher
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number of sample numbers from future experiments would be needed to elucidate
statistically significant differences between the two groups.

3.2.4 Up-regulation of anti-apoptotic proteins and down-regulation of
injury related proteins in treated cells following hypoxia
Analysis of mRNA samples showed significant differences in the expression of various
apoptosis and injury related markers in the cell samples (Figure 20). A significant
increase in the expression of anti-apoptotic markers Mcl-1(p<0.001) and Bcl-2 (p<0.01)
was observed in cells treated with 50μM GYY4137 in comparison to untreated hypoxic
cells. There was also a significant reduction in the expression of injury marker EDN-1 in
the treated samples (p<0.01) in comparison to the untreated hypoxia exposed cell
samples. However, a trend of decreased expression of pro-apoptotic molecules (not
statistically significant) was observed across all samples (whether treated or untreated)
consistently.
.
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Figure 14: Different combinations of warm and cold hypoxic times and resulting
impact on cell viability.
Preliminary experiments indicating little to no change in hypoxic sample’s cell viability
upon incremental increases in just the cold hypoxic time. Statistically significant negative
impact observed on cell viability in 4hours warm + 8 hours cold (p<0.05), 12hours warm
+ 24 hours cold (p<0.01) and 12 hours warm alone (p<0.001) conditions in comparison to
normoxic-healthy cells. (W = warm hypoxic hours, C = cold hypoxic hours; Values are
Mean ± SEM, n=4 in each group, * = p<0.05, ** = p<0.01, *** = p<0.001 using
Student’s t-test)
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Figure 15: Flow analysis scatter plots obtained from Annexin-V and 7-AAD staining
The plots above represent the healthy cells under normoxic conditions in incubator (A),
the hypoxic untreated samples (B) and cell samples supplemented with 50μM and 500μM
GYY4137 respectively(C & D). The x-axis is representative of Annexin-V stain and yaxis represents 7-AAD stain. The upper left quadrant marks the necrotic cells, lower left
quadrant has the healthy cells, the upper right quadrant shows the late apoptotic/
necroptotic cells while the lower right quadrant has the early apoptotic cells.
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Figure 16: Increased percentage of viable cells upon supplementation with
GYY4137.
Cell samples exposed to 12 hours hypoxia and 24 hours reoxygenation (at 37ºC) were
analyzed for cell viability using Annexin-V and 7-AAD stains with flow cytometer.
Adequate concentration of GYY4137 (50μM) helps mitigate effects of hypoxiareoxygenation injury in LLC-PK1 cells. The cell viability is significantly improved in the
treatment group (p<0.05) in comparison to the untreated group. (Values are Mean ± SEM,
n=3 in each group, * = p<0.05 using two-way ANOVA with Tukey’s test for multiple
comparisons)
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Figure 17: Trend depicting decrease in percentages of necrotic and late apoptotic
cells after supplementation with H2S donor.
The percentage of necrotic and late apoptotic cells is reduced to half the amount of that
observed in untreated samples after experiencing 12 hours of hypoxia at 37ºC followed by
24 hours of reoxygenation. The cells were analyzed using the Annexin-V and 7-AAD
stains using flow cytometer. (Red = percentage of necrotic cells, Blue = percentage of late
apoptotic/necroptotic cells; Values are Mean ± SEM, n=3 in each group, differences are
not statistically significant)
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Figure 18: Trend indicating reduction in percentage of cells with reactive oxygen
species upon H2S supplementation.
Following 12 hours of hypoxia, treated and untreated cell samples were stained with
DHR123 and analyzed with flow cytometer. The histographs from flow analysis show the
unstained-negative untreated (A), positive control - cells treated with 3% H2O2 in PBS for
10 minutes (B), and a sample of untreated cells after hypoxia (C). The bar graph in (D)
shows reduced percentage of cells with ROS upon supplementation with 50μM of
GYY4137 during hypoxic phase. (Mean ± SEM, n=4 in each group, differences
statistically not significant)
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Figure 19: Trend depicting decreased percentage of cells with depolarized
mitochondrial membrane in treated sample.
The scatter plots from flow analysis show healthy cells (A), heat killed positive control
(B) and untreated (DMEM only) cell sample (C) stained with JC-1 molecule following 12
hours of hypoxia at 37ºC. The bar graph (D) shows a trend of decrease in percentage of
cells with depolarized mitochondrial membrane upon addition of 50μM GYY4137 during
hypoxic conditions. (Values are Mean ± SEM, n=4 in each group, differences statistically
not significant)
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Figure 20: Up-regulation of anti-apoptotic proteins while down regulation of injury
markers observed with H2S supplementation.
Increase in mRNA expression of Bcl-2 and Mcl-1 (anti-apoptotic proteins) along with
decreased expression of injury marker EDN-1 observed in cells treated with 50μM
GYY4137. The pro-apoptotic markers were down regulated in all samples irrespective of
H2S supplementation. (Values are mean ± SEM and n=4 in each group; two-way
ANOVA with Tukey’s test for multiple comparisons used; * = p<0.05, *** = p<0.001)
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4

Discussion

Renal transplantation is considered to be the most effective renal replacement therapy in
ESRD patients. Due to the disparity between the organ demand and supply, the use of
marginal donors (such as DCD donors) has become acceptable. However, the DCD grafts
experience prolonged IRI and are more susceptible to failure and delayed graft function.
Thus, finding ways to mitigate IRI in these grafts has become the prime focus of the
transplant community.
Our lab has previously shown the protective effects of supplementation with exogenous
H2S on graft function after either prolonged warm ischemia or cold storage.90,112
However, the murine model of renal transplantation used in this study is the first of its
kind to use a combination of both warm ischemia and cold storage and mimics the clinical
model of a DCD transplant. The DCD murine model used in this study showed improved
graft function and survival rate in the recipients with concurrent exogenous (NaHS) and
endogenous (D-cysteine/3MST pathway) H2S supplementation. This is in accordance
with other renal IRI studies performed in mice or rats showing protective effects of either
exogenous H2S addition involving 30 minutes to 1 hour of pedicle clamping (warm
ischemia)84,90,112 or showing how endogenous H2S also helps mitigate effects of IRI in
renal models.113 L-cysteine is a widely used substrate for H2S production endogenously
through the CBS and CSE enzymatic pathways. It generally overshadows the role played
by D-cysteine in H2S production internally. However, a recent study by Shibuya and
Kimura (2013) showed that D-cysteine diminishes impact of IRI more effectively than Lcysteine because of its 80-fold greater H2S producing activity in the kidney.105 This is the
reason why I chose to incorporate a combination of D-cysteine and exogenous H2S
supplementation in our experimental study.
H2S supplementation in this model of prolonged warm ischemia and cold storage
followed by subsequent renal transplantation led to increased survival rate, faster
recovery of graft function and less renal injury in treatment group rats. By post-operative
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day 10, the treatment group’s serum creatinine was almost equivalent to the baseline
sham levels while it took almost 20 days for the untreated group to reach the baseline
levels. This indicates prevention of delayed graft function in the recipients that could help
eliminate the need for dialysis after the first week of transplantation. The urine
osmolality, on the other hand, was lower for both the untreated and treatment groups in
comparison to the sham group rats. Decreased urine osmolality is a marker of either
impaired renal function or diuresis in the transplant recipients as another study has
reported diuresis in the transplant recipients in an IRI model.112 However, further analysis
such as the glomerular filtration rate along with the concentration of various ions (like
sodium and potassium) in urine and blood serum can help elucidate the actual cause of
decrease in urine osmolality for the subjects in our study.
One of the ways in which our study is different from others is the length of the
experimental period (30 days). This helped us to look at the long-term effects rather than
limiting it to earlier time points of 2-weeks or less. Tissue analysis indicated comparable
amounts of acute tubular necrosis and apoptosis among the untreated and treatment group
rats. Other studies have observed comparable increases in apoptosis and necrosis in nontransplantation in-vivo IRI models involving clamping induced warm ischemia in renal
tissue84 and myocardium. 89,104
For studying the IRI mechanism at a cellular level, the proximal tubular epithelial kidney
cells are considered to be the prime choice. The reason for this preference stems from the
fact that maximum I/R injury is observed in the epithelial cells of the proximal tubular
region in the nephrons depicted by the loss of apical brush border.114 One can argue that
the in-vitro experiments are limited in their ability to exactly replicate the internal
physiologic environment as experienced by the cells during in-vivo IRI models, but they
are still considered to be the best way to tease apart the cellular signaling pathways and
mechanisms.
In-vitro studies have shown that the hypoxia-reoxygenation model mimics a similar kind
of injury as sustained by the kidney during in-vivo IRI. However, different studies vary in
the methods of inducing hypoxia that can involve the use of chemicals (mitochondrial
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electron transport chain inhibitors like rotenone, antimycin A and sodium azide),
enzymatic pathway (Glucose oxidase-GOX and Catalase-CAT; generally called the
GOX/CAT system) or a hypoxia chamber (varying concentrations of oxygen - 0.5% to
1% and carbon dioxide – 5% - 20%).114–117 For this study, I used a precisely regulated
hypoxia chamber (as described in methods) to induce the hypoxic injury at 1% oxygen for
12 hours and maintaining 37ºC temperature followed by 20-24 hours of reoxygenation.
The time interval for hypoxia was based on a number of optimization experiments with
varying time periods as was described in the results section.
Our in-vitro hypoxia-reoxygenation experiments corroborated results obtained in our invivo DCD murine model. The addition of slow releasing H2S donor (GYY4137) was able
to rescue the cells from in-vitro hypoxia-reoxygenation injury as observed by increased
percentage of cell viability and decreased percentage of necrosis and late apoptosis in the
specific cell samples containing 50μM GYY4137. Similar protective effects of H2S
supplementation have been observed in other in-vitro studies involving the use of NaHS
in either chemically induced hypoxia in human skin keratinocytes or hypoxia induced by
chamber in human umbilical vein endothelial cells (HUVECs).118,119 However, these
effects have not been tested in kidney cell lines. A study performed many years ago by
Wiegele et al. (1998) showed that the mechanisms of cell death happening from ATP
depletion involved apoptosis and necrosis. In their study, apoptosis was observed only at
early stages and only in a small proportion of cells while the necrotic pathway was the
major culprit of cell death especially with longer periods (more than 8 hours) of ATP
depletion.117 A similar trend was observed in our in-vitro model whereby the prolonged
hypoxic conditions triggered the necrotic cell death.
One challenge was to assess early apoptotic cells in-vitro. Studies by Bursch et al. in 1990
noted that the time span from initiation to completion of apoptosis could be as short as 23 hours.120,121 Hence, by the time the cells are analyzed, there is a high possibility that the
early apoptotic cells become late apoptotic or necroptotic. This explains why early
apoptosis might have gone un-detected in our in-vitro experiments. On the other hand,
contradictory findings have been reported in literature in regards to apoptosis versus
necrosis contribution to cell death. One study of cutaneous tissue transplantation has
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reported increased apoptosis along with necrosis following IRI119 and the same was
observed in our in-vivo model as well. However, it must be noted that IRI based in-vitro
studies of hypoxia-reoxygenation look at longer time points and generally report the late
apoptotic cells.
Although there might be differences in the extent of apoptosis and necrosis observed after
IRI, the cellular pathways and pathophysiology associated with the two processes is very
similar ultimately resulting in cell death. Both the processes stem from increased ROS
and mitochondrial membrane depolarization. Our in-vitro experiments showed a trend of
reduction in the percentage of cells with ROS in cell samples supplemented with H2S
donor. Despite the fact that the amount of ROS present in the treatment group was not
significantly lower than the untreated group, even a slight decline in ROS could
potentially prove beneficial for rescuing the cells considering the negative impact ROS
has on mitochondria and the cell as a whole. The use of stain DHR 123 for detection of
ROS has been well established in literature as it has been previously used for studying
oxidative burst in human granulocytes.122 One drawback for using this stain is its higher
sensitivity to H2O2 in comparison to other reactive molecules resulting from IRI such as
superoxides and per-oxy-nitrites. Superoxide constitutes majority of the ROS and is
formed mainly in the mitochondria where it then reacts with the mitochondrial enzymes
to form H2O2.123,124
The mitochondrial apoptotic pathway is one of the major contributors of apoptotic cell
death while the other pathway that feeds apoptosis is the signaling by death receptors. The
mitochondrial pathway involves the crucial process of mitochondrial outer membrane
permeabilization (MOMP).102,125 One of the ways in which this is achieved is the
formation of the permeability transition pore that leads to a change in the mitochondrial
membrane potential due to equilibration of ions across the membrane.126 This eventually
leads to swelling of the mitochondria followed by breaking of the outer membrane
producing MOMP.125 In this study, it was observed that the addition of H2S donor in
adequate amounts resulted in a decline in percentage of cells with depolarized
mitochondrial membrane. This indicates that H2S hinders the MOMP by preventing the
permeability transition pore from causing the leakage of ions and thereby impeding
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depolarization of the mitochondrial membrane. However, this study did not explore if
H2S actually blocks these pores or inhibits the formation of these pores to prevent
depolarization.
The second mechanism for MOMP is mediated by the members of the Bcl-2 protein
family. It is widely accepted that certain members of the Bcl-2 family are pro-apoptotic
(such as Bax, Bak or Bid) while others act as anti-apoptotic molecules (such as Bcl-2,
Mcl-1).46 The Bcl-2 is the prototype member of this family of proteins and all members
contain at least one Bcl-2 homology (BH) region. The mRNA expression of these
proteins was assessed via qRT-PCR in both the in-vivo and in-vitro samples. The in-vivo
samples showed up regulation of apoptotic proteins such as caspase-3 and Bax in the rats
from untreated group. Still other pro-apoptotic (Bid) and inflammatory (TNF-α)
molecules showed similar expression as the baseline sham levels. However, the same
apoptotic and inflammatory markers were highly down regulated in the treatment group
rats except the Bax protein that was being expressed at baseline levels. On the contrary,
the pro-apoptotic proteins depicted a trend of down regulation in both the treated as well
as untreated cell samples in the in-vitro experiments.
Previous studies have shown a link between Bax expression and induction of apoptosis in
cells.127 Bax and Bid are generally present in the cytosol of the cells. Upon initiation of
apoptotic signaling pathways, these molecules help in inducing MOMP and the eventual
leakage of cytochrome c and other proteins from the mitochondria that result in apoptosis
in the cells.125,128 However, these molecules are not solely responsible for MMPT as a
study by De Marchi et al. showed that blocking the pro-apoptotic proteins like the
Bax/Bid did not completely inhibit the depolarization of the mitochondrial membrane in
the cells.129 They also showed that other mechanisms like high intracellular
concentrations of Ca+2 could still result in MMPT in absence of Bax/Bid. This explains
some differences observed in the expression of pro-apoptotic proteins in the in-vivo and
in-vitro models in our study since the Bax was not upregulated in the LLC-PK1 cells
undergoing IRI but still apoptosis was observed in these samples.
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One anomaly observed in our in-vivo experiments was the up regulation of Bcl-2 in both
the untreated and the treatment group rats while our in-vitro hypoxia-reoxygenation
model showed a significant up regulation in the mRNA expression of anti apoptotic
proteins Mcl-1and Bcl-2 only in the cell samples treated with 50μM GYY4137. There
was also a significant decrease detected in the expression of injury marker EDN-1 in the
same cell samples that were supplemented with H2S donor in comparison to the untreated
cell samples. One of the reasons that can help explain this conflict between the results
from in-vivo and in-vitro experiments is the time point at which the data were collected.
The graft tissues used for qRT-PCR were collected from the renal transplant recipient rats
on post-operative day 3 while the mRNA was collected from the LLC-PK1 cells right
after experiencing 12 hours of warm hypoxia followed by 15 minutes of reoxygenation.
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5

Future Directions

Our in-vivo murine model, although first of its kind to mimic DCD renal transplantation,
studies the combined effect of increasing endogenous H2S production prior to ischemia
along with exogenous H2S supplementation during the cold storage phase of the graft. It
would be interesting to observe the two conditions separately and to see if the effects of
endogenous and exogenous H2S are synergic in nature. Further, the verification of various
apoptotic or anti-apoptotic proteins in the tissue samples using western blots might help
solidify the results obtained through mRNA analysis.
The results from in-vitro experiments did not show a large number of early apoptotic cells
after hypoxic injury and 24 hours of reoxygenation. However, the ROS and mitochondrial
membrane potential analysis that was performed after smaller periods or no
reoxygenation showed some differences between the untreated and treatment group
samples. It would be intriguing to measure percentage of apoptotic cells following smaller
periods of reoxygenation after the hypoxic injury. Maybe, a time-course experiment could
help shed some light on this phenomenon. In addition, to better understand the
mechanism of H2S action in mitochondrial apoptotic pathway, the leakage of
mitochondrial cytochrome c into the cytoplasm could be studied. This can be done by
separating the mitochondrial and cytosolic contents and then measuring the concentration
of cytochrome c in each separately. An increase in the ratio of the mitochondrial to
cytoplasmic cytochrome c in treated samples would indicate a definitive role of H2S in
preventing MOMP.
Our study focused on only one H2S releasing donor molecule (GYY4137). However, it
would be fascinating to see the effect of other H2S donor molecules that release H2S in a
targeted way or stimulate endogenous production of H2S. One such recently discovered
molecule is AP39 that is a targeted mitochondrial H2S donor. Since one of the major
apoptotic pathways and cell death mechanism involves the mitochondria, this molecule
might prove to be the ideal candidate for future studies.
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6

Conclusion and Significance

Our study is the first ever study looking at the use of H2S in a clinically relevant murine
model of DCD renal transplantation. Other studies that demonstrate the protective effects
of H2S against IRI do not involve the transplantation of the organ experiencing IRI into
the recipient. The few exceptional studies that do involve renal transplantation fail to
investigate the combined effect of warm ischemia and prolonged cold storage. In our
study, H2S supplementation resulted in increased survival and improved renal graft
function along with a significant decrease in histological injury among the treatment
group rats. The in-vitro model also recapitulated the protective role of slow releasing H2S
donor molecule (GYY4137) on the proximal tubular porcine kidney epithelial cells (LLCPK1) as shown by the reduction in depolarization of the mitochondrial membrane, the
ROS and the increased cell viability in treated cell samples. It also exemplifies an
important role played by the mitochondria in cell death caused by the hypoxiareoxygenation injury as depicted by up regulation of the mitochondrial associated antiapoptotic marker Bcl-2, Mcl-1 and decreased expression of pro-apoptosis related genes
such as Bax and Bid.
The results from this study illustrate the clinical significance of H2S mediated protective
pathways in IRI and the future of DCD transplants. Considering the short half-life of H2S
and its depletion by the time of transplantation in the recipients, it should be feasible to
make minimal changes to the current clinical protocol and adopt the use of H2S into
clinical practice. This transition would not only help to reduce the extent of IRI and
delayed graft function experienced by the DCD organs but may also help increase the
pool of donors that are deemed suitable for renal transplantation.

68

Bibliography
1.

St Peter WL. Introduction: chronic kidney disease: a burgeoning health epidemic. J
Manag Care Pharm. 2007;13(9 Suppl D):S2-S5.

2.

About Chronic Kidney Disease - The National Kidney Foundation.
https://www.kidney.org/kidneydisease/aboutckd. Accessed June 17, 2015.

3.

Weiner DE. Causes and consequences of chronic kidney disease: implications for
managed health care. J Manag Care Pharm. 2007;13(3 Suppl):S1-S9.

4.

Usrds. 2013 USRDS annual data report. 2013:464.

5.

Information CI for H. Canadian Organ Replacement Register Annual Report :
Treatment of End-Stage Organ Failure in Canada , 2003 to 2012. 2014.

6.

Murtagh FEM, Addington-Hall J, Higginson IJ. The prevalence of symptoms in
end-stage renal disease: a systematic review. Adv Chronic Kidney Dis.
2007;14(1):82-99. doi:10.1053/j.ackd.2006.10.001.

7.

Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic
renal failure. Lancet. 2000;356(9224):147-152. doi:10.1016/S01406736(00)02456-9.

8.

Torpy JM, Lynm C, Golub RM. Kidney Transplantation. JAMA J Am Med Assoc.
2011;305(6):634-634. doi:10.1001/jama.305.6.634.

9.

Dialysis | Definition of dialysis by Merriam-Webster. http://www.merriamwebster.com/dictionary/dialysis. Accessed June 18, 2015.

10.

Himmelfarb J, Ikizler TA. Hemodialysis. N Engl J Med. 2010;363(19):1833-1845.
doi:10.1056/NEJMra0902710.

11.

Hemodialysis: Treatment for Kidney Failure.
http://www.medicinenet.com/hemodialysis/article.htm. Accessed June 18, 2015.

69

12.

Daugirdas JT, Blake PG, Ing TS. Handbook of Dialysis. In: Handbook of Dialysis.
Vol 4th ed. Wolters Kluwer; 2006:323-336. http://www.amazon.ca/HandbookDialysis-John-TDaugirdas/dp/0781752531/ref=sr_1_1?s=books&ie=UTF8&qid=1434598272&sr=
1-1&keywords=9780781752534.

13.

Alloatti S, Manes M, Paternoster G, Gaiter AM, Molino A, Rosati C. Peritoneal
dialysis compared with hemodialysis in the treatment of end-stage renal disease. J
Nephrol. 13(5):331-342.

14.

Wu AW, Fink NE, Marsh-Manzi JVR, et al. Changes in quality of life during
hemodialysis and peritoneal dialysis treatment: generic and disease specific
measures. J Am Soc Nephrol. 2004;15(3):743-753.
doi:10.1097/01.ASN.0000113315.81448.CA.

15.

Purnell TS, Auguste P, Crews DC, et al. Comparison of life participation activities
among adults treated by hemodialysis, peritoneal dialysis, and kidney
transplantation: A systematic review. Am J Kidney Dis. 2013;62(5):953-973.
doi:10.1053/j.ajkd.2013.03.022.

16.

Nakamura-Taira N, Muranaka Y, Miwa M, Kin S, Hirai K. Views of Japanese
patients on the advantages and disadvantages of hemodialysis and peritoneal
dialysis. Int Urol Nephrol. 2013;45(4):1145-1158. doi:10.1007/s11255-012-0322x.

17.

Coping With The Top Five Side Effects of Dialysis - The National Kidney
Foundation. https://www.kidney.org/news/ekidney/january12/top5. Accessed June
24, 2015.

18.

Kidney Transplant - The National Kidney Foundation.
https://www.kidney.org/atoz/content/kidneytransnewlease. Accessed June 24,
2015.

70

19.

Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med. 1994;331(6):365376. doi:10.1056/NEJM199408113310606.

20.

Mathur AK, Ashby VB, Sands RL WR. Geographic variation in end-stage renal
disease incidence and access to deceased donor kidney transplantation. Am J
Transpl. 2010;10 (4 Pt 2):1069-1080.

21.

U.S. Renal Data System, USRDS 2014 Annual Data Report: Atlas of End-Stage
Renal Disease in the United States.; 2014. http://www.usrds.org/Default.aspx.

22.

Canadian Institute for Health Information. Deceased Organ Donor Potential in
Canada. Ottawa, ON; 2014.

23.

Metzger R, Delmonico FL, Feng S, Port FK, Wynn JJ, Merion RM. Expanded
criteria donors for kidney transplantation. Am J Transplant. 2003;3 Suppl 4:114125.

24.

Summers DM, Watson CJE, Pettigrew GJ, et al. Kidney donation after circulatory
death (DCD): state of the art. Kidney Int. 2015;(Dcd):1-9. doi:10.1038/ki.2015.88.

25.

Campbell GMD, Sutherland FR. Non-heart-beating organ donors as a source of
kidneys for transplantation: A chart review. Cmaj. 1999;160(11):1573-1576.

26.

Gagandeep S, Matsuoka L, Mateo R, et al. Expanding the donor kidney pool:
utility of renal allografts procured in a setting of uncontrolled cardiac death. Am J
Transplant. 2006;6(7):1682-1688. doi:10.1111/j.1600-6143.2006.01386.x.

27.

O’Neill S, Gallagher K, Hughes J, Wigmore SJ, Ross J a, Harrison EM. Challenges
in early clinical drug development for ischemia-reperfusion injury in kidney
transplantation. Expert Opin Drug Discov. 2015;10(7):753-762.
doi:10.1517/17460441.2015.1044967.

28.

Oniscu GC, Randle L V., Muiesan P, et al. In Situ Normothermic Regional
Perfusion for Controlled Donation After Circulatory Death-The United Kingdom
Experience. Am J Transplant. 2014;14(12):2846-2854. doi:10.1111/ajt.12927.

71

29.

Summers DM, Johnson RJ, Hudson A, Collett D, Watson CJ, Bradley JA. Effect of
donor age and cold storage time on outcome in recipients of kidneys donated after
circulatory death in the UK: A cohort study. Lancet. 2013;381(9868):727-734.
doi:10.1016/S0140-6736(12)61685-7.

30.

Cho YW, Terasaki PI, Cecka JM GD. Transplantation of kidneys from donors
whose hearts have stopped beating. N Engl J Med. 1998;338:221-225.

31.

Akoh J. Kidney donation after cardiac death. World J Nephrol. 2012;1(3):79.
doi:10.5527/wjn.v1.i3.79.

32.

Galliford J, Game DS. Modern renal transplantation: present challenges and future
prospects. Postgrad Med J. 2009;85(1000):91-101.
doi:10.1136/pgmj.2008.070862.

33.

Chandran S, Vincenti F. Clinical Aspects: Focusing on Key Unique Organ-Specific
Issues of Renal Transplantation. Cold Spring Harb Perspect Med.
2014;4(2):a015644-a015644. doi:10.1101/cshperspect.a015644.

34.

McDonald SP. Survival of recipients of cadaveric kidney transplants compared
with those receiving dialysis treatment in Australia and New Zealand, 1991-2001.
Nephrol Dial Transplant. 2002;17(12):2212-2219. doi:10.1093/ndt/17.12.2212.

35.

Tonelli M, Wiebe N, Knoll G, et al. Systematic review: Kidney transplantation
compared with dialysis in clinically relevant outcomes. Am J Transplant.
2011;11(10):2093-2109. doi:10.1111/j.1600-6143.2011.03686.x.

36.

Greco F, Fornara P, Mirone V. Renal transplantation: Technical aspects, diagnosis
and management of early and late urological complications. Panminerva Med.
2014;56(1):17-29.

37.

Jassal S V, Krahn MD, Naglie G, et al. Kidney transplantation in the elderly: a
decision analysis. J Am Soc Nephrol. 2003;14(1):187-196.
doi:10.1097/01.ASN.0000042166.70351.57.

72

38.

Schnuelle P, Lorenz D, Trede M, Van Der Woude F. Impact of renal cadaveric
transplantation on survival in end-stage renal failure: Evidence for reduced
mortality risk com- pared with hemodialysis during long-term follow-up. J Am Soc
Nephrol. 1998;9:2135-2141.

39.

Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on
dialysis, patients on dialysis awaiting transplantation, and recipients of a first
cadaveric transplant. N Engl J Med. 1999;341(23):1725-1730.
doi:10.1056/NEJM199912023412303.

40.

Rao P, Merion R, Ashby V, Port F, Wolfe R, Kayler L. Renal transplantation in
elderly patients older than 70 years of age: results from the Scientific Registry of
Transplant Recipients. Transplantation. 2007;83(8):1069-1074.

41.

Meier-Kriesche H-U, Schold JD, Srinivas TR, Reed A, Kaplan B. Kidney
transplantation halts cardiovascular disease progression in patients with end-stage
renal disease. Am J Transplant. 2004;4(10):1662-1668. doi:10.1111/j.16006143.2004.00573.x.

42.

Perović S, Janković S. Renal transplantation vs hemodialysis: Cost-effectiveness
analysis. Vojnosanit Pregl. 2009;66(8):639-644. doi:10.2298/VSP0908639P.

43.

Eltzschig HK, Eckle T. Ischemia and reperfusion—from mechanism to translation.
Nat Med. 2011;17(11):1391-1401. doi:10.1038/nm.2507.

44.

Duehrkop C, Rieben R. Ischemia/reperfusion injury: Effect of simultaneous
inhibition of plasma cascade systems versus specific complement inhibition.
Biochem Pharmacol. 2014;88(1):12-22. doi:10.1016/j.bcp.2013.12.013.

45.

Marsden VS, Strasser A. Control of apoptosis in the immune system: Bcl-2, BH3only proteins and more. Annu Rev Immunol. 2003;21(1):71-105.
doi:10.1146/annurev.immunol.21.120601.141029.

46.

Adams JM, Cory S. Bcl-2-regulated apoptosis: mechanism and therapeutic
potential. Curr Opin Immunol. 2007;19(5):488-496. doi:10.1016/j.coi.2007.05.004.

73

47.

Hotchkiss RS, Strasser A, McDunn JE, Swanson PE. Cell death. N Engl J Med.
2009;361(16):1570-1583. doi:10.1056/NEJMra0901217.

48.

Klionsky DJ. Autophagy: from phenomenology to molecular understanding in less
than a decade. Nat Rev Mol Cell Biol. 2007;8(11):931-937. doi:10.1038/nrm2245.

49.

Kroemer G, Jäättelä M. Lysosomes and autophagy in cell death control. Nat Rev
Cancer. 2005;5(11):886-897. doi:10.1038/nrc1738.

50.

Guan L-Y, Fu P-Y, Li P-D, et al. Mechanisms of hepatic ischemia-reperfusion
injury and protective effects of nitric oxide. World J Gastrointest Surg.
2014;6(7):122-128. doi:10.4240/wjgs.v6.i7.122.

51.

Malek M, Nematbakhsh M. Renal ischemia / reperfusion injury ; from
pathophysiology to treatment. J Ren Inj Prev. 2015;4(2):20-27.
doi:10.12861/jrip.2015.06.

52.

Sastre J, Serviddio G, Pereda J, et al. Mitochondrial function in liver disease. Front
Biosci. 2007;12:1200-1209.

53.

Aguilar HI, Botla R, Arora AS, Bronk SF, Gores GJ. Induction of the
mitochondrial permeability transition by protease activity in rats: A mechanism of
hepatocyte necrosis. Gastroenterology. 1996;110(2):558-566.
doi:10.1053/gast.1996.v110.pm8566604.

54.

Crow MT. The Mitochondrial Death Pathway and Cardiac Myocyte Apoptosis.
Circ Res. 2004;95(10):957-970. doi:10.1161/01.RES.0000148632.35500.d9.

55.

Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of
cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis.
Science. 1997;275(5303):1132-1136. doi:10.1126/science.275.5303.1132.

56.

Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes
cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell.
2000;102(1):33-42. doi:10.1016/S0092-8674(00)00008-8.

74

57.

Stratford May JW, Deng X. Principles of Molecular Medicine. Vol 2nd ed. (Runge
MS, Patterson C, eds.). Totowa, NJ: Humana Press; 2006. doi:10.1007/978-159259-963-9.

58.

Wang R. Two’s company, three's a crowd: can H2S be the third endogenous
gaseous transmitter? FASEB J. 2002;16(13):1792-1798. doi:10.1096/fj.020211hyp.

59.

Bogdan C. Nitric oxide and the immune response. Nat Immunol. 2001;2(10):907916. doi:10.1038/ni1001-907.

60.

Snijder PM, Van Den Berg E, Whiteman M, Bakker SJL, Leuvenink HGD, Van
Goor H. Emerging role of gasotransmitters in renal transplantation. Am J
Transplant. 2013;13(12):3067-3075. doi:10.1111/ajt.12483.

61.

Maines MD, Gibbs PEM. 30 Some years of heme oxygenase: From a “molecular
wrecking ball” to a “mesmerizing” trigger of cellular events. Biochem Biophys Res
Commun. 2005;338(1):568-577. doi:10.1016/j.bbrc.2005.08.121.

62.

Otterbein LE, Bach FH, Alam J, et al. Carbon monoxide has anti-inflammatory
effects involving the mitogen-activated protein kinase pathway. Nat Med.
2000;6(4):422-428. doi:10.1038/74680.

63.

Otterbein LE, Zuckerbraun BS, Haga M, et al. Carbon monoxide suppresses
arteriosclerotic lesions associated with chronic graft rejection and with balloon
injury. Nat Med. 2003;9(2):183-190. doi:10.1038/nm817.

64.

Chin BY, Jiang G, Wegiel B, et al. Hypoxia-inducible factor 1alpha stabilization
by carbon monoxide results in cytoprotective preconditioning. Proc Natl Acad Sci
U S A. 2007;104(12):5109-5114. doi:10.1073/pnas.0609611104.

65.

Warenycia MW, Goodwin LR, Benishin CG, Reiffenstein, R. J. Francom DM,
Taylor JD, Dieken FP. Acute hydrogen sulfide poisoning: demonstration of
selective uptake of sulfide by the brainstem by measurement of brain sulfide levels.
Biochem Pharmacol. 1989;38:973-981.

75

66.

Abe K, Kimura H. The possible role of hydrogen sulfide as an endogenous
neuromodulator. Off J Soc Neurosci. 1996;16(3):1066-1071.

67.

Zhong G, Chen F, Cheng Y, Tang C, Du J. The role of hydrogen sulfide generation
in the pathogenesis of hypertension in rats induced by inhibition of nitric oxide
synthase. Journal of hypertension. J Hypertens. 2003;21:1879-1885.

68.

Zhao W, Zhang J, Lu Y, Wang R. The vasorelaxant effect of H 2S as a novel
endogenous gaseous KATP channel opener. EMBO J. 2001;20:6008-6016.

69.

Dombkowski RA, Russell MJ, Olson KR. Hydrogen sulfide as an endogenous
regulator of vascular smooth muscle tone in trout. Am J Physiol Regul Integr Comp
Physiol. 2004;286(4):R678-R685. doi:10.1152/ajpregu.00419.2003.

70.

Hosoki R, Matsuki N, Kimura H. The possible role of hydrogen sulfide as an
endogenous smooth muscle relaxant in synergy with nitric oxide. Biochem Biophys
Res Commun. 1997;237(3):527-531. doi:10.1006/bbrc.1997.6878.

71.

Kolluru GK, Shen X, Bir SC, Kevil CG. Hydrogen sulfide chemical biology:
pathophysiological roles and detection. Nitric Oxide. 2013;35:5-20.
doi:10.1016/j.niox.2013.07.002.

72.

Zanardo RCO, Brancaleone V, Distrutti E, Fiorucci S, Cirino G, Wallace JL.
Hydrogen sulfide is an endogenous modulator of leukocyte-mediated
inflammation. FASEB J. 2006;20(12):2118-2120. doi:10.1096/fj.06-6270fje.

73.

Yonezawa D, Sekiguchi F, Miyamoto M, et al. A protective role of hydrogen
sulfide against oxidative stress in rat gastric mucosal epithelium. Toxicology.
2007;241(1-2):11-18. doi:10.1016/j.tox.2007.07.020.

74.

Laggner H, Hermann M, Esterbauer H, et al. The novel gaseous vasorelaxant
hydrogen sulfide inhibits angiotensin-converting enzyme activity of endothelial
cells. J Hypertens. 2007;25(10):2100-2104. doi:10.1097/HJH.0b013e32829b8fd0.

76

75.

Ali MY, Whiteman M, Low CM, Moore PK. Hydrogen sulphide reduces insulin
secretion from HIT-T15 cells by a KATP channel-dependent pathway. J
Endocrinol. 2007;195(1):105-112. doi:10.1677/JOE-07-0184.

76.

Yang G, Zhao K, Ju Y, et al. Hydrogen Sulfide Protects Against Cellular
Senescence via S-Sulfhydration of Keap1 and Activation of Nrf2. Antioxid Redox
Signal. 2013;18(15):1906-1919. doi:10.1089/ars.2012.4645.

77.

Calvert JW, Jha S, Gundewar S, et al. Hydrogen sulfide mediates cardioprotection
through nrf2 signaling. Circ Res. 2009;105(4):365-374.
doi:10.1161/CIRCRESAHA.109.199919.

78.

Chung KF. Hydrogen sulfide as a potential biomarker of asthma. Expert Rev
Respir Med. 2014;8(1):5-13. doi:10.1586/17476348.2014.856267.

79.

Chen YH, Yao WZ, Geng B, et al. Endogenous hydrogen sulfide in patients with
COPD. Chest. 2005;128(5):3205-3211. doi:10.1378/chest.128.5.3205.

80.

Fu Z, Liu X, Geng B, Fang L, Tang C. Hydrogen sulfide protects rat lung from
ischemia–reperfusion injury. Life Sci. 2008;82(23-24):1196-1202.
doi:10.1016/j.lfs.2008.04.005.

81.

Jha S, Calvert JW, Duranski MR, Ramachandran A, Lefer DJ. Hydrogen sulfide
attenuates hepatic ischemia-reperfusion injury: role of antioxidant and
antiapoptotic signaling. AJP Hear Circ Physiol. 2008;295(2):H801-H806.
doi:10.1152/ajpheart.00377.2008.

82.

Sodha NR, Clements RT, Feng J, et al. The effects of therapeutic sulfide on
myocardial apoptosis in response to ischemia–reperfusion injury☆☆☆. Eur J
Cardio-Thoracic Surg. 2008;33(5):906-913. doi:10.1016/j.ejcts.2008.01.047.

83.

Elrod JW, Calvert JW, Morrison J, et al. Hydrogen sulfide attenuates myocardial
ischemia-reperfusion injury by preservation of mitochondrial function. Proc Natl
Acad Sci. 2007;104(39):15560-15565. doi:10.1073/pnas.0705891104.

77

84.

Bos EM, Leuvenink HGD, Snijder PM, et al. Hydrogen sulfide-induced
hypometabolism prevents renal ischemia/reperfusion injury. J Am Soc Nephrol.
2009;20(9):1901-1905. doi:10.1681/ASN.2008121269.

85.

Koning AM, Frenay A-RS, Leuvenink HGD, van Goor H. Hydrogen sulfide in
renal physiology, disease and transplantation – The smell of renal protection. Nitric
Oxide. 2015;46:37-49. doi:10.1016/j.niox.2015.01.005.

86.

Winyard PG, Blake DR, Evans CH, eds. Free Radicals and Inflammation. Basel:
Birkhäuser Basel; 2000. doi:10.1007/978-3-0348-8482-2.

87.

Whiteman M, Winyard PG. Hydrogen sulfide and inflammation: the good, the bad,
the ugly and the promising. Expert Rev Clin Pharmacol. 2011;4(1):13-32.
doi:10.1586/ecp.10.134.

88.

Cheung NS, Peng ZF, Chen MJ, Moore PK, Whiteman M. Hydrogen sulfide
induced neuronal death occurs via glutamate receptor and is associated with
calpain activation and lysosomal rupture in mouse primary cortical neurons.
Neuropharmacology. 2007;53(4):505-514. doi:10.1016/j.neuropharm.2007.06.014.

89.

Sodha NR, Clements RT, Feng J, et al. The effects of therapeutic sulfide on
myocardial apoptosis in response to ischemia-reperfusion injury. Eur J Cardiothoracic Surg. 2008;33(5):906-913. doi:10.1016/j.ejcts.2008.01.047.

90.

Zhu JXG, Kalbfleisch M, Yang YX, et al. Detrimental effects of prolonged warm
renal ischaemia-reperfusion injury are abrogated by supplemental hydrogen
sulphide: An analysis using real-time intravital microscopy and polymerase chain
reaction. BJU Int. 2012;110(11 C). doi:10.1111/j.1464-410X.2012.11555.x.

91.

Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives.
Trends Cell Biol. 2001;9:372-377.

92.

Bradley J. TNF-mediated inflammatory disease. J Pathol. 2008;2:149-160.

78

93.

Yoshida L, Tsunawaki S. Expression of NADPH oxidases and enhanced H(2)O(2)generating activity in human coronary artery endothelial cells upon induction with
tumor necrosis factor-alpha. Int Immunopharmacol. 2008;10:1377-1385.

94.

Zelová H, Hošek J. TNF-α signalling and inflammation: interactions between old
acquaintances. Inflamm Res. 2013;62(7):641-651. doi:10.1007/s00011-013-0633-0.

95.

McCord JM, Fridovich I. The reduction of cytochrome c by milk xanthine oxidase.
J Biol Chem. 1968;243(21):5753-5760. doi:4972775.

96.

Nakano H, Nakajima A, Sakon-Komazawa S, Piao J-H, Xue X, Okumura K.
Reactive oxygen species mediate crosstalk between NF-κB and JNK. Cell Death
Differ. 2006;13(5):730-737. doi:10.1038/sj.cdd.4401830.

97.

Whiteman M, Li L, Kostetski I, et al. Evidence for the formation of a novel
nitrosothiol from the gaseous mediators nitric oxide and hydrogen sulphide.
Biochem Biophys Res Commun. 2006;343(1):303-310.
doi:10.1016/j.bbrc.2006.02.154.

98.

Schreier SM, Muellner MK, Steinkellner H, et al. Hydrogen Sulfide Scavenges the
Cytotoxic Lipid Oxidation Product 4-HNE. Neurotox Res. 2010;17(3):249-256.
doi:10.1007/s12640-009-9099-9.

99.

Whiteman M, Armstrong JS, Chu SH, et al. The novel neuromodulator hydrogen
sulfide: an endogenous peroxynitrite “scavenger”? J Neurochem. 2004;90(3):765768. doi:10.1111/j.1471-4159.2004.02617.x.

100. Whiteman M, Cheung NS, Zhu Y-Z, et al. Hydrogen sulphide: a novel inhibitor of
hypochlorous acid-mediated oxidative damage in the brain? Biochem Biophys Res
Commun. 2005;326(4):794-798. doi:10.1016/j.bbrc.2004.11.110.
101. Geng B, Chang L, Pan C, et al. Endogenous hydrogen sulfide regulation of
myocardial injury induced by isoproterenol. Biochem Biophys Res Commun.
2004;318(3):756-763. doi:10.1016/j.bbrc.2004.04.094.

79

102. Fu M, Zhang W, Wu L, Yang G, Li H, Wang R. Hydrogen sulfide (H2S)
metabolism in mitochondria and its regulatory role in energy production. Proc Natl
Acad Sci. 2012;109(8):2943-2948. doi:10.1073/pnas.1115634109.
103. Guo W, Kan J, Cheng Z, et al. Hydrogen Sulfide as an Endogenous Modulator in
Mitochondria and Mitochondria Dysfunction. Oxid Med Cell Longev.
2012;2012:1-9. doi:10.1155/2012/878052.
104. Sivarajah A, Collino M, Yasin M, et al. Anti-apoptotic and anti-inflammatory
effects of hydrogen sulfide in a rat model of regional myocardial I/R. Shock.
2009;31(3):267-274. doi:10.1097/SHK.0b013e318180ff89.
105. Shibuya N, Kimura H. Production of hydrogen sulfide from D-cysteine and its
therapeutic potential. Front Endocrinol (Lausanne). 2013;4(JUL):1-5.
doi:10.3389/fendo.2013.00087.
106. Shibuya N, Koike S, Tanaka M, et al. A novel pathway for the production of
hydrogen sulfide from D-cysteine in mammalian cells. Nat Commun. 2013;4:1366.
doi:10.1038/ncomms2371.
107. Whiteman M, Le Trionnaire S, Chopra M, Fox B, Whatmore J. Emerging role of
hydrogen sulfide in health and disease: critical appraisal of biomarkers and
pharmacological tools. Clin Sci (Lond). 2011;121(11):459-488.
doi:10.1042/CS20110267.
108. Li L, Whiteman M, Guan YY, et al. Characterization of a novel, water-soluble
hydrogen sulfide-releasing molecule (GYY4137): New insights into the biology of
hydrogen sulfide. Circulation. 2008;117(18):2351-2360.
doi:10.1161/CIRCULATIONAHA.107.753467.
109. Whiteman M, Perry A, Zhou Z, et al. Chemistry, Biochemistry and Pharmacology
of Hydrogen Sulfide. 2015;230. doi:10.1007/978-3-319-18144-8.
110. Fox B, Schantz JT, Haigh R, et al. Inducible hydrogen sulfide synthesis in
chondrocytes and mesenchymal progenitor cells: Is H2S a novel cytoprotective

80

mediator in the inflamed joint? J Cell Mol Med. 2012;16(4):896-910.
doi:10.1111/j.1582-4934.2011.01357.x.
111. Hine C, Harputlugil E, Zhang Y, et al. Endogenous Hydrogen Sulfide Production
Is Essential for Dietary Restriction Benefits. Cell. 2015;160(1-2):132-144.
doi:10.1016/j.cell.2014.11.048.
112. Lobb I, Mok A, Lan Z, Liu W, Garcia B, Sener A. Supplemental hydrogen
sulphide protects transplant kidney function and prolongs recipient survival after
prolonged cold ischaemia-reperfusion injury by mitigating renal graft apoptosis
and infl ammation. BJU Int. 2012;110(11 C). doi:10.1111/j.1464410X.2012.11526.x.
113. Bos EM, Wang R, Snijder PM, et al. Cystathionine -Lyase Protects against Renal
Ischemia/Reperfusion by Modulating Oxidative Stress. J Am Soc Nephrol.
2013;24(5):759-770. doi:10.1681/ASN.2012030268.
114. Ueda N, Kaushal GP, Hong X, Shah S V. Role of enhanced ceramide generation in
DNA damage and cell death in chemical hypoxic injury to LLC-PK1 cells. Kidney
Int. 1998;54(2):399-406. doi:10.1046/j.1523-1755.1998.00008.x.
115. Kurian GA, Pemaih B. Standardization of in vitro Cell-based Model for Renal
Ischemia and Reperfusion Injury. Indian J Pharm Sci. 2014;76(4):348-353.
doi:10.1016/S0140-6736(68)90219-5.
116. Hotter G, Palacios L, Sola A. Low O2 and high CO2 in LLC-PK1 cells culture
mimics renal ischemia-induced apoptosis. Lab Invest. 2004;84(2):213-220.
doi:10.1038/labinvest.3700026.
117. Wiegele G, Brandis M, Zimmerhackl LB. Apoptosis and necrosis during ischaemia
in renal tubular cells (LLC-PK1 and MDCK). Nephrol Dial Transplant.
1998;13(5):1158-1167. doi:10.1093/ndt/13.5.1158.
118. Yang C, Yang Z, Zhang M, et al. Hydrogen sulfide protects against chemical
hypoxia-induced cytotoxicity and inflammation in hacat cells through inhibition of

81

ROS/NF-kB/COX-2 pathway. PLoS One. 2011;6(7).
doi:10.1371/journal.pone.0021971.
119. Henderson PW, Singh SP, Belkin D, et al. Hydrogen Sulfide Protects Against
Ischemia-Reperfusion Injury in an In Vitro Model of Cutaneous Tissue
Transplantation. J Surg Res. 2010;159(1):451-455. doi:10.1016/j.jss.2009.05.010.
120. Bursch W, Kleine L, Tenniswood M. The biochemistry of cell death by apoptosis.
Biochem Cell Biol. 1990;88:1071-1074.
121. Bursch W, Paffe S, Putz B, Barthel G, Schulte- Hermann R. Determination of the
length of the Apoptosis Assays 389 histological stages of apoptosis in normal liver
and in altered hepatic foci in rats. Carcinogenesis. 1990;11:847-853.
122. Walrand S, Valeix S, Rodriguez C, Ligot P, Chassagne J, Vasson MP. Flow
cytometry study of polymorphonuclear neutrophil oxidative burst: A comparison of
three fluorescent probes. Clin Chim Acta. 2003;331(1-2):103-110.
doi:10.1016/S0009-8981(03)00086-X.
123. Turrens JF, Boveris A. Generation of superoxide anion by the NADH
dehydrogenase of bovine heart mitochondria. Biochem J. 1980;191(2):421-427.
124. Turrens JF, Freeman BA, Levitt JG, Crapo JD. The effect of hyperoxia on
superoxide production by lung submitochondrial particles. Arch Biochem Biophys.
1982;217(2):401-410. doi:10.1016/0003-9861(82)90518-5.
125. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science.
2004;305(5684):626-629. doi:10.1126/science.1099320.
126. Knudson CM, Brown NM. Mitochondria potential, bax “activation,” and
programmed cell death. Methods Mol Biol. 2008;414:95-108.
127. Pirot AL, Fritz KI, Ashraf QM, Mishra OP, Delivoria-Papadopoulos M. Effects of
severe hypocapnia on expression of Bax and Bcl-2 proteins, DNA fragmentation,

82

and membrane peroxidation products in cerebral cortical mitochondria of newborn
piglets. Neonatology. 2007;91(1):20-27. doi:10.1159/000096967.
128. Kroemer G, Galluzzi L, Brenner C. Mitochondrial Membrane Permeabilization in
Cell Death. Physiol Rev. 2007;87(1):99-163. doi:10.1152/physrev.00013.2006.
129. De Marchi U, Campello S, Szabò I, Tombola F, Martinou JC, Zoratti M. Bax does
not directly participate in the Ca2+-induced permeability transition of isolated
mitochondria. J Biol Chem. 2004;279(36):37415-37422.
doi:10.1074/jbc.M314093200.

83

Appendices
Appendix A: Preliminary data showing graft recovery following renal
transplantation with grafts that had experienced IRI.
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Serum creatinine levels of renal transplant recipients after receiving donor kidneys that
were clamped for 20 minutes and underwent a cold ischemic period of 18 hours in UW
solution only (untreated group), D-cysteine pre-op and UW solution plus 150μM NaHS
(treatment group) as well as sham-operated rats. (Mean values are shown, n=1)
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Appendix B: Ethics approval form for in-vivo experiments
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